

US00RE49835E

(19) United States

(12) Reissued Patent

Almeida et al.

(10) Patent Number: US RE49,835 E

(45) Date of Reissued Patent: *Feb. 13, 2024

(54) MOUSE CELL LINE AUTHENTICATION

(71) Applicant: United States of America, as

represented by the Secretary of Commerce, NIST, Gaithersburg, MD

(US)

(72) Inventors: Jamie L Almeida, Gaithersburg, MD

(US); Kenneth D. Cole, Gaithersburg,

MD (US)

(73) Assignee: United States of America as

Represented by the Secretary of Commerce, Gaithersburg, MD (US)

(*) Notice: This patent is subject to a terminal dis-

claimer.

(21) Appl. No.: 16/263,835

(22) Filed: **Jan. 31, 2019**

Related U.S. Patent Documents

Reissue of:

(64) Patent No.: 9,556,482
Issued: Jan. 31, 2017
Appl. No.: 13/935,285
Filed: Jul. 3, 2013

(51) Int. Cl.

C12Q 1/68 (2018.01) C12Q 1/6881 (2018.01)

(52) U.S. Cl.

CPC *C12Q 1/6881* (2013.01); *C12Q 2600/156* (2013.01); *C12Q 2600/16* (2013.01)

(58) Field of Classification Search

None

See application file for complete search history.

(56) References Cited

U.S. PATENT DOCUMENTS

5,599,666	\mathbf{A}	2/1997	Schumm et al.
5,843,660	\mathbf{A}	12/1998	Schumm et al.
6,156,512	\mathbf{A}	12/2000	Schumm et al.
6,251,592	B1	6/2001	Tang et al.
7,645,580	B2	1/2010	Barber et al.
8,409,806	B2	4/2013	Green et al.
10,745,753	B2 *	8/2020	Almeida C12Q 1/6881
2003/0180724	$\mathbf{A}1$	9/2003	Schumm et al.
2003/0224372	$\mathbf{A}1$	12/2003	Syndercombe-Court
2004/0137452	$\mathbf{A}1$	7/2004	Levett et al.
2006/0035236	$\mathbf{A}1$	2/2006	Keim et al.
2006/0263785	$\mathbf{A}1$	11/2006	Quaife
2009/0117542	$\mathbf{A}1$	5/2009	Maybruck et al.
2010/0062430	A 1	3/2010	Hauzenberger et al.

2010/0285463 A1	11/2010	Kronenberg et al.
2011/0171654 A1	7/2011	Green et al.
2011/0263437 A1	10/2011	Fang et al.
2011/0306505 A1	12/2011	Chang et al.
2012/0122093 A1	5/2012	Hennessy et al.

FOREIGN PATENT DOCUMENTS

\mathbf{EP}	0887426	A2	12/1998
EP	2010676	B1	1/2013
WO	WO/99/14371	$\mathbf{A}1$	3/1999
WO	WO/99/61659	$\mathbf{A}1$	12/1999
WO	WO/01/92575	$\mathbf{A}1$	12/2001
WO	WO/02/068685	A 2	9/2002
WO	WO/03/102236	A 1	12/2003
WO	WO/2004/008841	A 2	1/2004
WO	WO/2009/003654	A 2	1/2009
WO	WO/2009/003654	A3	1/2009
WO	WO/2011/032054	A 2	3/2011
WO	WO/2011/066467	A 2	6/2011
WO	WO/2011/133935	A 2	10/2011
WO	WO/2011/133947	A 2	10/2011
WO	WO/2012/067901	A 1	5/2012

OTHER PUBLICATIONS

Almeida et al. (BMC Biotechnology, 2011, vol. 11, p. 1-10, IDS reference).*

Primary Examiner — Sharon Turner (74) Attorney, Agent, or Firm — Daphne Burton; Burton IP Law Group

(57) ABSTRACT

A multiplex polymerase chain reaction assay that targets nine tetranucleotide short tandem repeat (STR) markers in the mouse genome. Unique profiles were obtained from seventy-two mouse samples that were used to determine the allele distribution for each STR marker. Correlations between allele fragment length and repeat number were determined with DNA Sanger sequencing. Genotypes for L929 and NIH3T3 cell lines were shown to be stable with increasing passage numbers as there were no significant differences in fragment length with samples of low passage when compared to high passage samples. In order to detect cell line contaminants, primers for two human STR markers were incorporated into the multiplex assay to facilitate detection of human and African green monkey DNA. This multiplex assay is the first of its kind to provide a unique STR profile for each individual mouse sample and can be used to authenticate mouse cell lines.

10 Claims, 11 Drawing Sheets

Specification includes a Sequence Listing.

^{*} cited by examiner

SEQ ID NO.	STR	GENBANK ACCESSION #	LOCATION ON CHROMOSOME (BP)	PRIMERS (5'-3')	PRIMER
~~~~	<del>6</del> <del>-</del> <del>2</del> <del>-</del> <del>-</del> <del>2</del> <del>-</del> <del>-</del> <del>2</del> <del>-</del> <del>-</del> <del>2</del> <del>-</del>	NT_039674.8	60271556-60271705	F: [FAM] - TCTTTCTCCTTTTGTGTCATGCSEC III NO. 100   R: GTTTCTTGCTAAATAACTAAGCAAGTGAACAGASEC III NO. 100   R: GTTTCTTGCTAAATAACTAAGCAAGTGAACAGASEC III NO. 100   R. GTTTCTTGCTAAATAACTAAGCAAGTGAACAGASEC III NO. 100   R. GTTTCTTGCTAAATAACTAAGCAAGTGAACAGASEC III NO. 100   R. GTTTCTTGCTAAATAATAACTAAGCAAGAGTGAACAGASEC III NO. 100   R. GTTTCTTGCTAAATAAATAACTAAGCAAGAAGTGAACAGASEC III NO. 100   R. GTTTCTTGCTAAATAAATAACTAAGCAAGAACAGASEC III NO. 100   R. GTTTCTTGCTAAAATAAATAACTAAGCAAGAACAAGASEC III NO. 100   R. GTTTCTTTGCTAAAATAAAAAAAAAAAAAAAAAAAAAAA	0.200
N	4-2	NT_187032.1	82068280-82068580	F: [FAM] -AAGCTTCTCTGGCCATTTGA (SEQ. ED NO. E) 0. R:GTTCATAAACTTCAAGCAATGACA (SEQ. ED NO. E)	0.125
സ	<u>-</u>	NT_039353.8	51601265-51601685	F: [FAM] - AGTCCACCCAGTGCATTCTC (SEC. NO. 18) R: GTTTCTTCATGTGGCTGGTATGCTGTT (SEC. NO. 18)	0.075
4	7-5	NT_039474.8	74395400-74395000	F:[VIC]-GGATTGCCAAGAATTTGAGG (SEQ.EDNO.18) R:GTTTCTTTCCTGAGTTGTGGACAGGGTTA (SEQ.EDNO.28)	0.080
LO	15-5 5-3	NT_039617.8	4930200-4930500	F:[NED]-TCTGGGGGGGTGTCTGTCATA (SEC. 183)   R:GTTTCTTCAGGGAGGAGGAGTGTGTTTCTTCAGGGAGGAGGAGTGTGTTTTCTTCAGGGAGGAGGAGTGTTTTCTTCAGGGAGGAGGAGTGTTTTCTTCAGGGAGGAGGAGTTTTTCTTCAGGGAGGAGGAGTTTTTTTT	0.060
G	4-9	NT_039360.8	142021975-142022270	F: [NED] - TTTGCAACAGCTCAGTTTCC (SEC. 180 NO. 28) R: GTTTCTTAATCGCTGGCAGATCTTAGG (SEQ. 180 NO. 28)	0.100
	7	NT_039548.8	38480950–38481170	F: [PET] - CAAAATTGTCATTGAACACATGTAA (SEC. 1823) 0.200 R:GTTTCATTGGTCAAGAAATACTGAAGTACAA (SEC. 182) NO. 200	0.200 300
Φ	<b>S</b>	NT_109320.5	112641540-112641821	F: [PET] - CGTTTTACCTGGCTGACACA (SEQ. ED NO. 24) R: GTTTCTTTGGTTTAAAACTCAATACCAAACAA (SEQ. ED NO. 24)	0.300
<u>ග</u>	×	NT_039706.8	110959842–110960080	F:[PET]-GGATGGATGGATGGATGAAA (SER) NO 200 200 200 200 200 200 200 200 200 20	0.300 (%) (%) (%)
78	D8S1106	NT_167187.1	12835860-12836150		
29	D4S2408	NT_006316.16	31304210-31304514	F: [NED] - TCATTTCCATAGGGTAAGTGAAAA (SEC. 1820 SEC. 1820	0.200

Feb. 13, 2024

US RE49,835 E

18-3       18-3 F: TCTHTCTCCTTTTGTGTCATGC SEQ. ID NO. 33       281-313       54         4-2       18-3 R: GTCAAAGTTGGGGTTACAGAATG* SEQ. ID NO. 35       217-248       57         4-2 F: AGCTTCTCTGGCCATTTGA SEQ. ID NO. 35       217-248       57         6-7 R: GTCACACCCCAGTGCATTCT SEQ. ID NO. 37       333-515       60         6-7 R: GCATGTGGCTGGTATGCTGTT SEQ. ID NO. 39       318-360       60         9-2 F: GGCTCTCTCACACCTCATCC* SEQ. ID NO. 40       157-222       60         15-3 F: TCTGGGCTGTCTGTCATAA SEQ. ID NO. 41       157-222       60         15-3 F: TCTGGGCGTGTCTGTCATAA SEQ. ID NO. 43       276-311       52         6-4 F: TTTGCAACAGCTGTCTAAACACATGTAA* SEQ. ID NO. 44       12-1 F: CAAAATTGTCATGAACACATGTAA* SEQ. ID NO. 45       222-259       55         12-1 F: CAAAATTGTCATGACACATGTAA* SEQ. ID NO. 45       258-298       60         5-5 F: CGTTTTACCTGGCTGACACA SEQ. ID NO. 45       258-298       60         5-5 F: CGTTTTACCTGGCTGACACA SEQ. ID NO. 48       357-442       54         X-1 F: GAATGGTTGCTGACACA SEQ. ID NO. 49       357-442       54         X-1 F: GAATGGTTGCTGTAACAGATGCATATATCA SEQ. ID NO. 50       357-442       54				
4-2 R: GTCAAAGTTGGGGTTACAGAATG* SEQ. ID NO. 35       217-248         4-2 F: AAGCTTCTCTGGCCATTTGA SEQ. ID NO. 35       217-248         4-2 R: GTTCATAAACTTCAGCATGCA SEQ. ID NO. 36       333-515         6-7 F: AGTCCACCCAGTGCATTCTC SEQ. ID NO. 38       318-360         9-2 F: GGCTCTCTCACACCTCATCC* SEQ. ID NO. 40       15-3 F: TCTGGGCGTGTTGTCATAA SEQ. ID NO. 41       157-222         15-3 F: TCTGGGCGTGTTGTCATAA SEQ. ID NO. 42       157-222         6-4 F: TTTGCAACAGCTCAGTTTC SEQ. ID NO. 43       276-311         6-4 F: TTTGCAACAGCTCAGTTTAGG SEQ. ID NO. 43       276-311         6-4 F: TTTGCAACAGCTCAGTTTAGG SEQ. ID NO. 45       258-298         12-1 F: CAAAATTGTCATGACACA SEQ. ID NO. 45       258-298         5-5 F: CGTTTTACCTGGCTGACACA SEQ. ID NO. 45       258-298         5-5 F: CGTTTTACCTGGCTGACACA SEQ. ID NO. 48       357-442         X-1 R: GAATGGTTGCTGTAAA SEQ. ID NO. 49       357-442         X-1 R: GAATGGATGAAATACAAGATGGCATTATCA SEQ. ID NO. 50       357-442	ر ج م د ک	18-3 F: TCTTCCTTTGTGTCATGC SEQ. ID NO. 33	- 2 - 2 - 2 - 3	Š
4-2 F: AGCTTCTCTGGCCATTTGA SEQ. ID NO. 35       217-248         4-2 R: GTTCATAAACTTCAAGCAATGACA SEQ. ID NO. 36       333-515         6-7 F: AGTCCACCCAGTGCATTCTC SEQ. ID NO. 38       333-515         9-2 F: GCATGTGGCTGGTATGCTGTT SEQ. ID NO. 39       318-360         9-2 F: GCTCTCTCACACCTCATCC* SEQ. ID NO. 40       15-3 F: TCTGGGCGTGTTGTCATAA SEQ. ID NO. 41       157-222         6-4 F: TTTGCAACAGCTGTCATAA SEQ. ID NO. 43       276-311         6-4 F: TTTGCAACAGCTGGTGTTCC SEQ. ID NO. 43       276-311         6-4 F: TTTGCAACAGCTGGTAAA SEQ. ID NO. 44       222-259         12-1 F: CAAAATTGTCATGAG SEQ. ID NO. 45       222-259         12-1 F: CAAAATTGTCATGACACA SEQ. ID NO. 45       258-298         5-5 F: CGTTTTACCTGGCTGACA SEQ. ID NO. 47       258-298         5-5 F: CGTTTTACCTGGCTGACA SEQ. ID NO. 49       357-442         X-1 F: GGATGGATGATATATCAAGATGATATCA SEQ. ID NO. 50       357-442		18-3 R. GTCAAAGTTGGGGTTACAGAATG*SEQ. 10 NO. 34		
6-7 F: GTTCATAAACTTCAAGCAATGACA SEQ. ID NO. 36 6-7 F: AGTCCACCCAGTGCATTCTC SEQ. ID NO. 37 6-7 R: GCATGTGGCTGGTATGCTGTT SEQ. ID NO. 38 9-2 P: GGCTCTCTCACACCTCATCC* SEQ. ID NO. 39 9-2 R: GTCCATGAATCCACACTCATCC* SEQ. ID NO. 40 15-3 F: TCTGGGCGTGTTCATAA SEQ. ID NO. 41 15-3 R: GTTCTCAGGGAGGTGTCTTCATAA SEQ. ID NO. 42 15-3 R: GTTCTCAGGGAGGAGTGTTCC SEQ. ID NO. 43 15-4 F: TTTGCAACAGCTCAGTTTCC SEQ. ID NO. 43 12-1 F: CAAAATTGTCATTGAACACATGTAA* SEQ. ID NO. 45 12-1 R: GCAATGGTCAAGAATACTGAAGTACAA SEQ. ID NO. 47 12-1 R: GCAATGGTCAAGAAATACTGAAGTACAA SEQ. ID NO. 47 5-5 F: CGTTTTACCTGGCTGACACA SEQ. ID NO. 47 5-5 F: CGTTTTACCTGGCTGACACA SEQ. ID NO. 48 5-5 R: GATGGTTGCTGTCAACA SEQ. ID NO. 48 5-7-442 X-1 F: GAATGGTTGAAAA SEQ. ID NO. 49 5-7-442		4-2 F. AAGUTTOTOTGECCATTIGA SEQ. ID NO. 35		S
6-7 F: AGTCCACCAGTGCATTCTC SEQ. ID NO. 37  6-7 R: GCATGTGGCTGGTATGCTGTT SEQ. ID NO. 38  9-2 9-2 F: GGCTCTCTCACACCTCATCC* SEQ. ID NO. 40  9-2 P: GCCTCTCTCACACCTCATCC SEQ. ID NO. 40  15-3 F: TCTGGGCGTGTCTGTCATA SEQ. ID NO. 41  15-3 R: GTTCTCAGGAGGAGTGTGCT SEQ. ID NO. 42  15-3 R: GTTCTCAGGAGGAGTGTGCT SEQ. ID NO. 42  15-3 R: GATCGCTGCTGTCATA SEQ. ID NO. 43  12-1 F: CAAAATTGTCATTGAACACATGTAA* SEQ. ID NO. 45  12-1 F: GAATGGTCAAGAATACTGAAGTACAA SEQ. ID NO. 46  5-5 F: CGTTTTACCTGGCTGACACA SEQ. ID NO. 47  5-5 F: CGTTTTACCTGGCTGACACA SEQ. ID NO. 48  5-5 F: GATGGTTGCTGACAA SEQ. ID NO. 48  5-6 R: GATGGTTGCTGAAA SEQ. ID NO. 48  7-1 R: GAAGGTATATATCAAAA SEQ. ID NO. 49  7-1 R: GAAGGTATATATCAAAA SEQ. ID NO. 49  7-1 R: GAAGGTATATATCAAAA SEQ. ID NO. 49  7-1 R: GAAGGTATATATCAAGATGCATTATCA SEQ. ID NO. 50		4-2 R. GITCATAACITCAAGCAATGACA SEC. ID N		
6-7 R: GCATGTGGCTGGTATGCTGTT SEQ. ID NO. 38  9-2 F: GCCTCTCTCACACCTCATCC* SEQ. ID NO. 39  9-2 R: GTCCATGAATCCAGACATTCC SEQ. ID NO. 40  15-3 F: TCTGGGCGTGTCTGTCATAA SEQ. ID NO. 41  15-3 F: TCTGGGCGTGTCTGTCATAA SEQ. ID NO. 42  15-3 R: GTTCTCAGGGAGGAGTGTCT SEQ. ID NO. 43  15-1 F: CAAACTGTCATCAGTTTCC SEQ. ID NO. 43  12-1 F: CAAAATTGTCATTGAACACTGTAA* SEQ. ID NO. 45  12-1 F: CAAAATTGTCATTGAACACTGTAA* SEQ. ID NO. 46  5-5 F: CGTTTTACCTGGCTGACACA SEQ. ID NO. 47  5-5 F: CGTTTTACCTGGCTGACACA SEQ. ID NO. 48  5-5 F: CGTTTTACCTGGCTGACACA SEQ. ID NO. 48  X-1 F: GGATGGATGGATGAAA SEQ. ID NO. 49  X-1 F: GGATGGATGGATGAAA SEQ. ID NO. 49  X-1 R: GAAGGTATATATCAAGAATACTCA SEQ. ID NO. 50	C	6-7 F. AGTCCACCAGTGCATTCTC SEQ. 1D N	30° CC	<b>©</b>
9-2 F: GGCTCTCTCACACCTCC* SEQ. ID NO. 39 318-360 9-2 R: GTCCATGAATCCAGACATTCC SEQ. ID NO. 40 15-3 F: TCTGGGCGTGTCTGTCATA SEQ. ID NO. 42 15-3 F: TCTGGGCGTGTCTGTCATA SEQ. ID NO. 42 15-3 F: GTTCTCAGGGAGGGGTGTGCT SEQ. ID NO. 42 6-4 F: TTTGCAACAGGTGTGCT SEQ. ID NO. 43 276-311 6-4 F: TTTGCAACAGGTGTGCT SEQ. ID NO. 43 12-1 F: GAATCGTTGAACACATGTAA* SEQ. ID NO. 45 12-1 R: GCAATGGTCAACAGAATACTGAAGTACAA SEQ. ID NO. 46 5-5 F: CGTTTTACCTGGCTGACACA SEQ. ID NO. 47 5-5 R: GATGCTTGCTGGCACACA SEQ. ID NO. 48 5-5 R: GATGCTTGCCTGTTCCTAGC SEQ. ID NO. 48 X-1 F: GGATGGATGGATGAAA SEQ. ID NO. 49 X-1 F: GAATGGATGGATGAAA SEQ. ID NO. 49 X-1 R: GAAGGTATATATCAAGATGGCATTATCA SEQ. ID NO. 50		ON ON ON COURT BUILDER SECTION OF 19		
5-3   9-2 R: GTCCATGAATCCAGACATTCC SEQ. ID NO. 40 15-3 F: TCTGGGCGTGTCTGTCATAA SEQ. ID NO. 41 15-3 R: GTTCTCAGGGAGGAGTGTCT SEQ. ID NO. 42 6-4 F: TTTGCAACAGGTGTTCC SEQ. ID NO. 43 6-4 F: TTTGCAACAGGTGTTTCC SEQ. ID NO. 43 12-1 F: CAAAATTGTCATTGAACACATGTAA* SEQ. ID NO. 45 12-1 F: GCAATGGTCAAGAATACTGAAGTACAA SEQ. ID NO. 46 5-5 F: CGTTTTACCTGGCTGACACA SEQ. ID NO. 47 5-5 R: GATGCTTGCTGTTCCTAGC SEQ. ID NO. 48 5-5 R: GATGCTTGCTGTTCCTAGC SEQ. ID NO. 49 7-1 F: GGATGGATGGATGAAA SEQ. ID NO. 49 7-1 R: GAAGGTATATATCAAGATGGCATTATCA SEQ. ID NO. 50	() ()	9-2 F. GGCTCTCACACCTCATCC* SEQ. 1D N	9 8 8 8	<b>O</b>
5-3 15-3 F: TCTGGGCGTGTCTGTCATAA SEQ. ID NO. 41 15-3 R: GTTCTCAGGGAGTGTGCT SEQ. ID NO. 42 6-4 F: TTTGCAACAGCTCAGTTTCC SEQ. ID NO. 43 6-4 R: GAATCGCTGGCAGATCTTAGG SEQ. ID NO. 44 12-1 F: CAAAATTGTCATTGAACACTGTAA* SEQ. ID NO. 45 12-1 R: GCAATGGTCAAGAAATACTGAAGTACAA SEQ. ID NO. 46 5-5 F: CGTTTTACCTGGCTGACACA SEQ. ID NO. 47 5-5 F: GATGCTTGCCTGTTCCTAGC SEQ. ID NO. 48 X-1 R: GAAGGTATATATCAAGATGGCATTATCA SEQ. ID NO. 49 X-1 R: GAAGGTATATATCAAGATGGCATTATCA SEQ. ID NO. 50		9-2 R. GICATGAATCAGACATTCC SEEQ. ID NO. 2		
15-3 R: GTTCTCAGGGAGGTGTGCT SEQ. ID NO. 42  6-4 F: TTTGCAACAGCTCAGTTTCC SEQ. ID NO. 43  2-1	رب درب درب	15-3 F. TCTGGGGGTGTCTGTCATAA SEQ. 10 NO.	CC - CS	<b>O</b>
6-4 F: TITIGCAACAGCTCAGTTTCC SEQ. ID NO. 43  2-4 R: GAATCGCTGGCAGATCTTAGG SEQ. ID NO. 44  2-1 12-1 F: CAAAATTGTCATTGAACACATGTAA* SEQ. ID NO. 45  12-1 R: GCAATGGTCAAGAAATACTGAAGTACAA SEQ. ID NO. 46  5-5 F: CGTTTTACCTGGCTGACACA SEQ. ID NO. 47  5-5 F: GATGCTTGCTTGCTTCCTAGC SEQ. ID NO. 48  X-1 F: GGATGGATGGATGAAA SEQ. ID NO. 49  X-1 R: GAAGGTATATTCAAGATGCATTATCA SEQ. ID NO. 50		15-3 R. GITCICAGGAGGAGIGIGCISEQ. ID NO. A		
2-1 12-1 F: CAAATTGTCATTGAACACATGTAA* SEQ. ID NO. 45 222-259 12-1 R: GCAATGGTCAAGAAATACTGAAGTACAA SEQ. ID NO. 46 25-5 F: CGTTTTACCTGGCTGACACA SEQ. ID NO. 47 25-5 R: GATGCTTGCTGACACA SEQ. ID NO. 48 357-442 X-1 F: GGATGGATGGATGAAA SEQ. ID NO. 49 357-442 X-1 R: GAAGGTATATCAAGATGGCATTATCA SEQ. ID NO. 50	T C	6-4 F. TIGGAGGEORGITAG SEQ. 10 NO. 2	3	
2-1   12-1 F; CAAAATTGTCATTGAACACATGTAA* SEQ. ID NO. 45   222-259   12-1 R; GCAATGGTCAAGAATACTGAAGTACAA SEQ. ID NO. 46   258-298   5-5 F; CGTTTTACCTGGCTGACACA SEQ. ID NO. 47   5-5 R; GATGCTTGCCTGTTCCTAGC SEQ. ID NO. 48   357-442   X-1 F; GGATGGATGGATGAAA SEQ. ID NO. 50   357-442		6-4 R. GAATCECTGGCAGATCTTAGG SEC. ID N		
12-1 R: GCAATGGTCAAGAATACTGAAGTACAA SEQ. ID NO. 46 5-5 F: CGTTTTACCTGGCTGACACA SEQ. ID NO. 47 5-5 R: GATGCTTGCCTGTTCCTAGC SEQ. ID NO. 48 X-1 F: GGATGGATGAAA SEQ. ID NO. 49 X-1 R: GAAGGTATATCAAGATGGCATTATCA SEQ. ID NO. 50	4	12-1 F. CAMATTGTCATTGAACACATGTAA* SEQ. 10 NO. 2	000 000 000 000 000 000 000 000 000 00	
5-5 F: CGTTTTACCTGGCTGACACA SEQ. ID NO. 47  5-5 R: GATGCTTGCCTGTTCCTAGC SEQ. ID NO. 48  X-1 F: GGATGGATGGATGGATGAAA SEQ. ID NO. 49  X-1 R: GAAGGTATATTCAAGATGGCATTATCA SEQ. ID NO. 50		12-1 R. GCANTGGTCAAGAANTACTGAAGTACAA SEQ. 10 NO. 1		
5-5 R. GATGCTTGCCTGTTCCTAGC SEQ. ID NO. 48  X-1 F. GGATGGATGGATGAAA SEQ. ID NO. 49  X-1 R. GAAGGTATATCAAGATGGCATTATCA SEQ. ID NO. 50	L? L?	5-5 F. CETTACTEGITAACACA SEQ. ID NO. 2	258-298 -298	<b>O</b>
X-1 F. GGATGGATGGATGAAA SEQ. ID NO. 49 X-1 R. GAAGGTATATCAAGATGGCATTATCA SEQ. ID NO. 50		5-5 R. GATGCTTGCTGTTCCTAGC SEQ. ID N		
X-1 R. GAAGGTATATCAAGATGGCATTATCA SEQ. ID NO. 50	<b>**</b>	X-1 F. GGATGGATGGATGAAA SECO. ID N	No.	Š
		X-1 R. GAAGGTATATCAAGATGGCATTATCA SEQ. 10 NO. 50		

DEFINING STR FRAGMENT LENGTH WITH CORRELATING REPEAT NUMBER


STR	REPEAT MOTIF	ALLELE DISTRIBUTION AND CORRELATING FRAGMENT LENGTHS
18-3	[ATCT]n	137 146 150 154 158 162 166 171 175 179 12.2 15 16 <b>17 18 19</b> 20 21 <b>22</b> 23
4-2	[GATA]n[GATG]n	209 213 216 217 220 221 222 224 225 228 232 236 240 244 248 14 15 15.3 <b>16</b> 16.3 <b>17</b> 17.1 <b>17.3</b> 18 18.3 19.3 <b>20.3 21.3 22.3</b> 23.3
2-9	[CTAT]n	333 337 341 345 349 352 355 356 360 363 364 366 368 376 377 388 12 13 14 15 16 17 17.318 19 19.3 20 20.1 21 23 23.1 26
9-2	[TAGA]n[AGAT]n	188 192 204 219 220 223 227 231 235 7.1 8.1 11.1 <b>15</b> 15.1 <b>16 17 18</b> 19
15-3	[TAGA]n	157 165 169 177 181 184 189 193 196 200 204 208 212 216 220 222 12 14 <b>15 17 18 18.3 19.3</b> 20.3 <b>21.3</b> 22.3 23.3 <b>24.3</b> 25.3 26.3 27.3 28.1
6-4	[ATAG]n[ATGA][TAGA]n	276 285 286 289 290 293 294 297 298 301 302 307 311 11.2 13.3 14 14.3 15 15.3 16 16.3 17 17.3 18 19 20
12-1	[AGAT]n[GATA]n	222 226 227 230 231 234 235 238 239 242 246 247 250 254 259 15 <b>16</b> 16.1 <b>17</b> 17.1 <b>18</b> 18.1 19 19.1 20 21 <b>21.1</b> 22 23 24.1
5-5	[TATC]n	326 330 334 338 342 346 350 354 365 11 <b>12 13 14 15 16 17</b> 18 21
X-1	[ATAG]n[ATGA]n	380 385 389 393 397 401 404 405 409 413 421 428 448 20 21 22 <b>23</b> 24 <b>25</b> 25.3 <b>26 27</b> 28 30 32 37


Feb. 13, 2024


COMPLETE GENETIC PROFILES OF SIX MOUSE CELL LINES


					1					I.	
GELL LINE	OKIGIN	18-3		4-7	<i>)-</i> 0	3-Z	15-3	<b>6-4</b>	12-1	<b>၃-</b> ၃	X-1
NIH3T3	NIH Swiss	17, 19	19	19.3, 19.3	12, 12	2 15, 16	6 20.3	14.3, 14.3	20, 20	14, 15	25, 25
L-929	C3H/An	16, 16		20.3, 20.3	12, 12	2 15, 15	5 24.3, 25.3, 26.3	16, 16	16, 16	14, 14	26, 27
MC3T3-E1	C57BL/6	15, 1	2	20.3, 20.3	17, 17	7   17,18	3 22.3	17, 17	17, 17	17, 17	28, 28
RAW264.7	Balb/c	18, 18		22.3, 22.3	12, 12	2 15, 15	5 22.3	17, 17	16, 16	14, 14	24, 24
P3X63Ag8.653	Balb/c	<u>7</u> ,	<u>6</u>	21.3, 21.3	12, 12	2   15, 16	6 22.3, 23.3	17, 18	16, 16	13, 14	25, 25
HK-PEG-1	Balb/c	18, 19		21.3, 21.3	12, 12	2   15, 15	5 22.3, 23.3	17, 18	16, 16	13, 14	25, 25

FIG. 4









12-1 5-5
17
7.1
20
17
OUT OF RANGE
JL STOCK# 928

FIG. 9

MOUSE DNA SAMPLE         ORIGIN         18.3         4.2         6.7         9.2         15.3         6.4         12.1           SMUJ         JL STOCK# 687         20         18.3         1.2         15         25.3         14.3         16           WUSBEU         JL STOCK# 145         19         20.3         1.4         16         18.3         17         16           AJ         JL STOCK# 145         19         20.3         1.4         16         22.3         17         16           NODISHILTJ         JL STOCK# 1976         18         18.3         1.4         15         22.3         17         16           NODISHILTJ         JL STOCK# 1976         18         18.3         1.4         15         22.3         17         16           NODISHILTJ         JL STOCK# 2105         19         19.3         1.5         22.3         17         17           PWKPH         JL STOCK# 2105         19         19.3         1.2         1.5         21.3         1.7         16           CD1/IOR MALE         ZYAGEN#GM-150F         17         18.3         1.2         1.5         22.3         17.3         17         16           ARRJ <t< th=""><th></th><th></th><th></th><th></th><th></th><th>MOU</th><th>USE STR MARKERS</th><th>(ERS</th><th></th><th></th><th></th></t<>						MOU	USE STR MARKERS	(ERS			
JLSTOCK#687 20 18.3 12 15 25.3 14.3 17.3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	MOUSE DNA SAMPLE	ORIGIN	18-3	4-2	<i>1</i> -9	9-2	15-3	6-4	12-1	2-2	<b>1-X</b>
JLSTOCK# 145 19 20.3 14 16 18.3 17.3 17.5 JLSTOCK# 646 18 21.3 12 15 22.3 17 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	SM/J		70	18.3	12	15	25.3	14.3	16	14	26
JLSTOCK# 646 18 21.3 12 15 22.3 17 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	WSB/EIJ		19		14	16	18.3	17.3		14	21
JLSTOCK# 1976 18 18.3 14 15 22.3 15.3 15.3 JLSTOCK# 2105 19 19.3 19 15 22.3 16,17 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	A/J		18				22.3	17		16,17	27
JLSTOCK# 2105  JLSTOCK# 3715  JLSTOCK# 3715  JLSTOCK# 3715  ZVAGEN#GM-150M  T7  ZVAGEN#GM-150M  JLSTOCK# 648  JLSTOCK# 648  JLSTOCK# 669  JLSTOCK# 669  JLSTOCK# 669  JLSTOCK# 669  JLSTOCK# 77  JLSTOCK	NOD/SHILTJ	1	48	<u></u> ∞:		15	22.3	15.3	17	15	26
JLSTOCK#3715       19       19.3       15       7.1       15       15       161         ZYAGEN#GM-150M       17       19.3       12,15       15       21.3       14.3,16       17         ZYAGEN#GM-150F       17       18.3       12,15       15       22.3,23.3       16       17         JLSTOCK# 648       17       20.3       17       15       20.3       17       1         JLSTOCK# 2282       19       19.3       12       15       22.3       17.3       1         JLSTOCK# 2789       16       20.3       16       16       16       16       16       17       1         JLSTOCK# 2789       18       18.3       18       7.1       14       17       1         JLSTOCK# 3720       23       17       60k706       7.1       17       18       2         JLSTOCK# 577       17       19.3       14       15       24.3       15.3       1         JLSTOCK# 550       15       17       17       17       18       2         JLSTOCK# 560       15       17       17       17       18       2         JLSTOCK# 560       15       17	NZO/HLLTJ	I	19			15	22.3	16,17	17	12	24
ZYAGEN#GM-150M       17       19.3       12,15       15       21.3       14.3.16       17         ZYAGEN#GM-150F       17       18.3       12,15       15       22.3,23.3       16       17         JLSTOCK# 648       17       20.3       17       15       20.3       17       17         JLSTOCK# 3070       22       19.3       12       15       20.3       17.3       1         JLSTOCK# 5282       19       19.3       12       15       22.3       17.3       1         JLSTOCK# 669       16       20.3       15       16       20.3       17       14       17       1         JLSTOCK# 1800       17       19.3       12       15       20.3       14.3       1         JLSTOCK# 1800       17       19.3       17       17       18       2         JLSTOCK# 570       23       17       17       18       2         JLSTOCK# 550       15       17       17       18       2         JLSTOCK# 550       15       17       17       17       18       2         JLSTOCK# 550       15       17       17       17       17       18	PWK/PH		19	၂၀၈	15	7.1	15	15	6.1	15	20
ZYAGEN#GM-150F       17       18.3       12,15       15       22.3,23.3       16         JLSTOCK# 648       17       20.3       17       15       20.3       17         JLSTOCK# 3070       22       19.3       12       15       20.3       17.3         JLSTOCK# 650       16       20.3       15       15       22.3       17.3         JLSTOCK# 657       21       16.3       16       16       16       16       17       14.3         JLSTOCK# 1800       17       19.3       12       15       20.3       17       14.3         JLSTOCK# 1800       17       19.3       12       15       20.3       14.3         JLSTOCK# 3720       23       17       60476       7.1       17       18         JLSTOCK# 677       17       19.3,20.3       14       17       18         JLSTOCK# 550       16       17       17       17       18         JLSTOCK# 550       15       17       17       18         JLSTOCK# 550       15       17       17       17       18         JLSTOCK# 550       15       17       17       17       17       18	CD1/ICR MALE	ZYAGEN#GM-150M	17		2,1		21.3	14.3,16	17,18	15	25
JLSTOCK# 648         17         20.3         17         15         20.3         17           TF/J         JLSTOCK# 3070         22         19.3         12         15         20.3         17.3           TF/J         JLSTOCK# 2282         19         19.3         12         15         22.3         17.3           EJJ         JLSTOCK# 669         16         20.3         16         16         20.3         17         14.3           EJJ         JLSTOCK# 1800         17         18.3         18         7.1         14         17         18           S         JLSTOCK# 1800         17         19.3         12         15         20.3         14.3         18           JLSTOCK# 3720         23         17         000000         7.1         17         18         18         18.3         14.3         15.3         14.3         15.3         14.3         15.3         14.3         15.3         14.3         14.3         14.3         14.3         14.3         14.3         14.3         14.3         14.3         14.3         14.3         14.3         14.3         14.3         14.3         14.3         14.3         14.3         14.3         14.3	CD1/ICR FEMALE	ZYAGEN#GM-150F	17		2,1	15	22.3,23.3	16	19	14,15	25,26
TF/J JLSTOCK#3070 22 19.3 12 15 20.3 17.3 TF/J JLSTOCK#2282 19 19.3 12 15 22.3 17.3 17.3 JLSTOCK#669 16 20.3 15 16 22.3 14.3 17 15 JLSTOCK#657 21 16.3 16 16 20.3 17 17 19.3 12 JLSTOCK# 3720 23 17 19.3 14 15 20.3 14.3 18 JLSTOCK# 3720 23 17 19.3 14 15 20.3 14.3 18 JLSTOCK# 77 17 19.3,20.3 14 15 24.3 15.3 18 JLSTOCK# 731 16 17 17 13 7.1 17 18 18 JLSTOCK# 731 16 17 17 17 18 18 JLSTOCK# 550 15 17 17 18 JLSTOCK# 550 17 20.3 12 15 25.3 17	AKR/J		17	20.3			20.3	17	16	=	26
TF/J         JLSTOCK# 2282         19         19.3         12         15         23.3         17.3           JLSTOCK# 669         16         20.3         15         15         22.3         14.3         17           EIJ         JLSTOCK# 657         21         16.3         16         16         20.3         17         17           JLSTOCK# 1800         17         19.3         12         15         20.3         14.3         17           JLSTOCK# 1800         17         19.3         17         18         17         18           JLSTOCK# 3720         23         17         00110F         7.1         17         18           JLSTOCK# 677         17         19.3,20.3         14         15         24.3         15.3           JL STOCK# 550         15         17         17         17         18         18           JL STOCK# 550         15         17         17         17         18         17           JL STOCK# 486         17         20.3         17         7.1         17         18         17           JL STOCK# 486         17         20.3         12         25.3         17         17 <td>ALR/LT</td> <td>I</td> <td>22</td> <td>တ</td> <td></td> <td>15</td> <td>20.3</td> <td>17.3</td> <td>21</td> <td>15</td> <td>27</td>	ALR/LT	I	22	တ		15	20.3	17.3	21	15	27
JLSTOCK# 669       16       20.3       15       15       22.3       14.3         JLSTOCK# 57       21       16.3       16       16       16       20.3       17         JLSTOCK# 1800       17       19.3       12       15       20.3       14.3         JLSTOCK# 3720       23       17       001 06       7.1       17       18         JLSTOCK# 677       17       19.3,20.3       14       15       24.3       15.3         JLSTOCK# 550       15       17       17       17       18       17         JLSTOCK# 550       15       17       17       17       18       18         JLSTOCK# 550       15       17       17       17       18       18         JLSTOCK# 486       17       17       17       17       17       18       17		JL STOCK# 2282	19	δ			23.3	17.3	16	17	28
JLSTOCK# 657       21       16.3       16       16       16       16       16       16       16       17       17       17       18.3       18       7.1       14       17       17       17       14.3       17       14.3       17       14.3       18       17       14.3       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18       18	C58/J	l .	16				22.3	14.3	18	16	25
JLSTOCK# 2799       18       18.3       18       7.1       14       17         JLSTOCK# 1800       17       19.3       12       15       20.3       14.3         JLSTOCK# 3720       23       17       000T 0F       7.1       17       18         JLSTOCK# 677       17       19.3,20.3       14       15       24.3       15.3         JLSTOCK# 550       15       17       17       18       17         JLSTOCK# 486       17       20.3       12       15       25.3       17	CE/1		21	60.			20.3	41	<b>G</b> J	13	74
JLSTOCK# 1800       17       19.3       12       15       20.3       14.3       20         JLSTOCK# 3720       23       17       OUT OF RANGE       7.1       17       18       21.         JLSTOCK# 677       17       19.3,20.3       14       15       24.3       15.3       17         JLSTOCK# 550       15       17       17       17       17       18       24.         JLSTOCK# 486       17       20.3       12       15       17       16       17       16	CZECHI/EIJ		18			7.1	14	11	17.1	15	25.3
JLSTOCK# 3720       23       17       OUT OF RANGE       7.1       17       19.3,20.3       14       15       24.3       15.3       17         JLSTOCK# 550       15       17       17       17       17       17       18       24.3         JLSTOCK# 550       15       17       17       17       17       18       24.         JLSTOCK# 486       17       20.3       12       15       25.3       17       16	FVB/NJ		17	9.			20.3	14.3	20	14	97
JLSTOCK# 677         17         19.3,20.3         14         15         24.3         15.3         17           JLSTOCK# 731         16         17         17         17         17         18         24.           JLSTOCK# 486         17         20.3         12         15         17         16         17         16           JLSTOCK# 486         17         20.3         12         15         17         16	JF1/MS		23	17	OUTOF	7.1	17	18	21.1	18	32
JLSTOCK# 731         16         17         13         7.1         17         18         24.           JLSTOCK# 550         15         17         17         17         18         24.           JLSTOCK# 486         17         20.3         12         15         25.3         17         16	MA/MYJ	STOCK#		19.3,20.	14		24.3	15.3	21	14	23
JLSTOCK# 550         15         17         7.1         17         18         24.           JLSTOCK# 486         17         20.3         12         15         15         17         16	MOLC/RK	JL STOCK# 731	16	17	13	7.1	17	18		18	32
JL STOCK# 486 17 20.3 12 15 25.3 17 1	MOLF/EIJ	JL STOCK# 550	15			7.1	17	18		14	32
	MRL/MPJ	JL STOCK# 486	17			15	25.3	17	16	15	26

FIG. 9 (Cont.)

					MOUSE	JSE STR MARKERS	ERS			
MOUSE DNA SAMPLE	ORIGIN	18-3	4-2	<b>2-9</b>	7-6	15-3	6-4	12-1	<b>9-</b> 9	X-1
MSM/MS	JL STOCK# 3719	18	18	26	7.1	17	20	18.1	21	37
NON/SHILT	JL STOCK# 1290	17	20.3	15	15	22.3	14.3	16.1	13	25
NOR/LTJ	JL STOCK# 2050	18	18.3	14	15	20.3	15.3	17	15	27
NZW/LACJ	JL STOCK# 1058	17	17.3	15	15	22.3	17	18	11	25
PL/J	JL STOCK# 680	18	19.3	12	15	22.3	11	16	14	26
RIIIS/J	JL STOCK# 683	18	19.3	14	15	25.3	16	17	15	25
SB/LEJ	JL STOCK# 269	16	18.3	13	16	20.3	17	17	17	26
SEA/GNJ	JL STOCK# 644	18	21.3	12	15	23.3	17	17	15,16	28
SJL/J	JL STOCK# 686	17	19.3	12	<b>9</b> 1	22.3	14	17	14	26
SPRET/EIJ	JL STOCK# 1146	OUT OF RANGE	OUTOF RANGE	17.3	15.1	OUT OF RANGE	11.2	17.1	17	17.1
NIH3T3	ATCC#CRL-1658	17,19	19.3	12	15,16	20.3	14.3	20	14,15	25
L929	ATCC#CCL-1	16	20.3	12	15	24.3,25.3,26.3	16	16	14	26,27
MC3T3-E1 SUBCL 4	ATCC#CRL-2593	15	20.3	17	17,18	22.3	17	17	17	28
W-20-17	ATCC#CRL-2623	16,18	20.3,23.3	12,17	18	22.3	17	16,17	12,17	27
HK-PEG-1	ATCC#CCL-189	18,19	21.3	12	15	22.3,23.3	17,18	16	13,14	25
P3X63AG8.653	ATCC#CRL-1580	18,19	21.3	12	15,16	22.3,23.3	17,18	16	13,14	25
RAW 264.7	ATCC#TIB-71	18	22.3	12	15	22.3	17	16	14	24
M. DUNNI	ATCC#CRL-2017	15	17.1	20.1,23.1	11.1	12		17,19,21	13,16	OUT OF: RANGE:

FIG. 9 (Cont.)

### MOUSE CELL LINE AUTHENTICATION

Matter enclosed in heavy brackets [] appears in the original patent but forms no part of this reissue specification; matter printed in italics indicates the additions made by reissue; a claim printed with strikethrough indicates that the claim was canceled, disclaimed, or held invalid by a prior post-patent action or proceeding.

# STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH/DEVELOPMENT

The subject matter of this patent application was invented under the support of at least one United States Government ¹⁵ contract. Accordingly, the United States Government may manufacture and use the invention for governmental purposes without the payment of any royalties.

# CROSS-REFERENCE TO RELATED APPLICATIONS

The present application claims priority to provisional application Ser. No. 61/692,761, filed on or about Aug. 24, 2012, entitled "Mouse Cell Line Authentication" naming the same inventors as in the present application. The contents of this provisional application are incorporated by reference herein, the same as if fully set forth.

### SEQUENCE LISTING

The present application has a sequence listing set forth in a computer-readable file submitted on May 31, 2023, that is titled as follows: "16263835_ST25_05242023.txt." Said 35 computer-readable file has a size of 11 KB and is hereby incorporated by reference in the application, the same as if fully set forth.

### BACKGROUND OF THE INVENTION

Field of Invention

The present disclosure relates to cell lines and mouse strains, more particularly, to mouse cell line authentication. Description of Related Art

Cell line authentication is becoming increasingly important. For example, cell line authentication is now required by some journals prior to publication. In some cases, cell line authentication may be mandatory before receiving funding from some granting agencies.

The Federal Drug Administration has also instituted a requirement for the authentication of cell lines used to produce pharmaceuticals. Methods are currently in place for authenticating human cell lines using multiplex PCR assays that target short tandem repeat (STR) markers in the human genome and are capable of generating a unique individual genotypic profile. Cell repositories may now genotype their human cell lines using at least eight human STR markers including a marker for amelogenin, the sex identification 60 locus.

Large databases of STR profiles may be used to confirm genotypes of human cell lines. These databases may also be used to provide a record of previously misidentified or cross-contaminated human cell lines. The American Type 65 Culture Collection (ATCC) website maintains an updated list of misidentified human cell lines. Although there are

2

successful methods in place for human cell line authentication, methods for nonhuman cell lines are not well established.

Mouse cell lines are commonly used to study human genes and disease. Mouse cells may also be used in the biomanufacturing of recombinant proteins and may also function as feeder cells for embryonic stem cells.

In the prior art, there are a number of techniques used to identify mouse cell lines or mouse strains, including but not limited to microsatellite markers (simple sequence length polymorphism (SSLP) or STR markers), single nucleotide polymorphisms (SNPs), and species-specific primers. One of the most commonly used laboratory strains is the Mus musculus domesticus strain. This strain may be difficult to genotype due to many shared alleles as a result of extensive breeding.

There have been published reports of multiplexing mouse SSLPs post-PCR by pooling the amplified products to distinguish between different strains of inbred mice. However, most of the microsatellite markers that have been used for these purposes are dinucleotide in nature, mainly CA repeats, which may result in noisy stutter and have relatively high mutation frequencies when compared to tetranucleotide repeats. The reduced stutter associated with tetranucleotide repeats may allow for easier interpretation of single and mixed profiles.

There is a need for mouse cell line authentication based on tetranucleotide repeats, as opposed to microsatellite markers that are dinucleotide in nature.

Current methods may lack the resolution to differentiate between individual mice of the same subspecies. SNPs may be well-conserved between inbred mice of the same strain. Thus, it may be difficult to differentiate between interstrain mice using this method. Even an extensive array containing over 600,000 mouse SNPs may still be unable to identify individual mice within the same subspecies.

Species-specific primers may be used to determine the origin of species for cell lines. However, species-specific primers may lack specificity to identify at the individual level.

For human cell lines, practices have been adopted that are currently used to identify such cells. These practices are based on the detection of short tandem repeat (STR) mark45 ers. However, for the large volume of research that is performed using nonhuman cell lines (mouse, hamster, monkey, etc.), there are no STR marker assays that are able to uniquely and unequivocally identify a particular cell line.

There is further a need for a mouse cell line authentication assay that uniquely identifies cell lines at the individual level.

### BRIEF SUMMARY OF DISCLOSURE

The present disclosure addresses the needs described above by providing a PCR assay for mouse cell line authentication. The present assay may be used to authenticate mouse cell lines resulting in unique profiles for individual mouse samples based on tetranucleotide repeats that are stable with high passage number in the two different cell lines tested.

In accordance with one embodiment of the present disclosure, a method is provided for determining the alleles present in a DNA sample. The method comprises obtaining a DNA sample to be analyzed; and selecting a set of STR marker loci of the DNA sample to be analyzed that can be amplified together in a multiplex amplification reaction,

wherein the set of STR marker loci are selected from the group consisting of: 18-3, 4-2, 6-7, 9-2, 15-3, 6-4, 12-1, 5-5 and X-1.

The method further comprises providing a set of oligonucleotide primer pairs, wherein each oligonucleotide primer pair in the set flanks a single locus in the set of STR marker loci, and wherein each primer pair is capable of amplification of a single locus from the set of STR marker loci in a multiplex amplification reaction. The method also comprises co-amplifying the set of STR marker loci in a multiplex amplification reaction, wherein the product of the multiplex amplification reaction comprises a mixture of amplified alleles from each of the co-amplified loci in the set of STR marker loci. Finally, the method comprises evaluating the products of the co-amplification reaction to determine the alleles present at each of the loci analyzed in the set of STR marker loci within the DNA sample.

In accordance with another embodiment of the present disclosure, a kit is provided for determining the alleles present in a DNA sample to be analyzed. The kit comprises oligonucleotide primer pairs for co-amplifying a set of STR marker loci of at least one DNA sample to be analyzed. The set of loci comprises one or more of STR loci selected from the group consisting of STR marker loci 18-3, 4-2, 6-7, 9-2, 15-3, 6-4, 12-1, 5-5 and X-1.

These, as well as other objects, features and benefits will now become clear from a review of the following detailed description of illustrative embodiments and the accompanying drawings.

### BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 is a table illustrating primers for STR amplification and their corresponding chromosomal locations in accordance with the present disclosure.

FIG. 2 is a table illustrating sequencing primers and their respective amplicon size range as well as annealing temperatures in accordance with the present disclosure.

FIG. 3 is a table defining STR fragment length and corresponding repeat number in accordance with the present 40 disclosure.

FIG. 4 is a table illustrating the complete genetic profiles of six mouse cell lines in accordance with the present disclosure.

FIG. **5** is a genetic profile of an NIH3T3 cell line using the 45 multiplex assay of the present disclosure.

FIG. 6 illustrates the results obtained when a human contaminant is detected in an NIH3T3 STR profile in accordance with one embodiment of the present disclosure.

FIG. 7 is a genetic profile of a RAW 264.7 cell line using 50 the multiplex assay of the present disclosure.

FIG. 8 is a mixture of NIH3T3 and RAW 264.7 cell lines detected using the multiplex assay of the present disclosure.

FIG. 9 is a table containing the STR profiles showing the allele ranges for the markers from mouse cell lines, mouse 55 strains, and wild mice.

### **DEFINITIONS**

Allele: The term "allele" as used herein refers to a genetic 60 variation associated with a gene or a segment of DNA, i.e., one of two or more alternate forms of a DNA sequence occupying the same locus.

Amplicon/amplification product/amplified sequence: The terms "amplicon," "amplification product" and "amplified 65 sequence" are used interchangeably herein and refer to a broad range of techniques for increasing polynucleotide

4

sequences, either linearly or exponentially and can be the product of an amplification reaction. An amplicon can be double-stranded or single-stranded, and can include the separated component strands obtained by denaturing a double-stranded amplification product. In certain embodiments, the amplicon of one amplification cycle can serve as a template in a subsequent amplification cycle. Exemplary amplification techniques include, but are not limited to, PCR or any other method employing a primer extension step. Other nonlimiting examples of amplification include, but are not limited to, ligase detection reaction (LDR) and ligase chain reaction (LCR). Amplification methods can comprise thermal-cycling or can be performed isothermally. In various embodiments, the term "amplification product" and "amplified sequence" includes products from any number of cycles of amplification reactions.

Amplify: As used herein, "amplify" refers to the process of enzymatically increasing the amount of a specific nucleotide sequence. This amplification is not limited to but is generally accomplished by PCR. As used herein, "denaturation" refers to the separation of two complementary nucleotide strands from an annealed state. Denaturation can be induced by a number of factors, such as, for example, ionic strength of the buffer, temperature, or chemicals that disrupt 25 base pairing interactions. As used herein, "annealing" refers to the specific interaction between strands of nucleotides wherein the strands bind to one another substantially based on complementarity between the strands as determined by Watson-Crick base pairing. It is not necessary that complementarity be 100% for annealing to occur. As used herein, "extension" refers to the amplification cycle after the primer oligonucleotide and target nucleic acid have annealed to one another, wherein the polymerase enzyme catalyzes primer extension, thereby enabling amplification, using the target 35 nucleic acid as a replication template.

Detecting: The terms "detecting" and "detection" are used in a broad sense herein and encompass any technique by which one can determine the presence of or identify a nucleic acid sequence. In some embodiments, detecting comprises quantitating a detectable signal from the nucleic acid, including without limitation, a real-time detection method, such as quantitative PCR ("Q-PCR"). In some embodiments, detecting comprise's determining the sequence of a sequencing product or a family of sequencing products generated using an amplification product as the template; in some embodiments, such detecting comprises obtaining the sequence of a family of sequencing products. In other embodiments detecting can be achieved through measuring the size of a nucleic acid amplification product.

Locus-specific allelic DNA size marker: The term "locusspecific allelic DNA size marker" as used herein refers to a nucleic acid size standard for one or more alleles for a particular STR locus or marker. Those of skill in the art may variably refer to this as an "allelic ladder." The allelic ladder serves as a reference standard and nucleic acid size marker for the amplified alleles from the locus. In some embodiments, the allelic ladder can comprise size standards for the alleles of different STRs. In some embodiments, the allelic ladder can be made of DNA. In some embodiments, the allelic ladder can be made of non-naturally occurring nucleic acid analogs. The different individual size standards within an allelic ladder can, in some embodiments, be labeled with a detectable label, e.g., a fluorophore. In some embodiments, the allelic ladder components are labeled with the same fluorophore. In some embodiments, the allelic ladder components are labeled with different fluorophores. The size standards can be selected to work for a specific pair (or

pairs) of oligonucleotides primers. For example, if a first set of primers for marker X with a tetranucleotide repeat produces a 150 base pair amplicon corresponding to allele 1, the corresponding allelic ladder component will serve as a size standard for the 150 base amplicons; while a second pair of primers for marker X produces a 154 base pair amplicon corresponding to allele 2, the corresponding allelic ladder component will serve as a size standard for the 154 base amplicons. Thus different size standards for different size amplicons of the same marker are contemplated. The size standard for a given amplicon derived from a given allele may have nucleic acid base sequence that is the same or different than the nucleic acid base sequence of the amplicon or allele from which the amplicon is derived. For allele  $_{15}$ analysis in electrophoresis systems the size standard can be selected so as to have the same electropheretic mobility as the amplicon of interest. Alternatively, in some embodiments, the size standard can be selected so as to have different electropheretic mobility than the amplicon of inter- 20 est, given an understanding of the predicable nature of the difference; the identity of the amplicons could be determined. For allele analysis in mass spectroscopy systems the size standard (weight/charge ratio, not electropheretic mobility) can be selected so as to have the same signal as the 25 amplicon of interest. Alternatively, in some embodiments, the size standard (weight/charge ratio, not electropheretic mobility) can be selected so as to have the different separation properties than the amplicon of interest, given an understanding of the predicable nature of the difference, the identity of the amplicons could be determined.

Primer: The term "primer" refers to a polynucleotide (oligonucleotide) and analogs thereof that are capable of selectively hybridizing to a target nucleic acid or "template", a target region flanking sequence or to a corresponding primer-binding site of an amplification product; and allows the synthesis of a sequence complementary to the corresponding polynucleotide template, flanking sequence or amplification product from the primer's 3' end. Typically a primer can be between about 10 to 100 nucleotides in length and can provide a point of initiation for template-directed synthesis of a polynucleotide complementary to the template, which can take place in the presence of appropriate enzyme(s), cofactors, substrates such as nucleotides 45 (dNTPs) and the like.

Amplification Primer/Oligonucleotide primer: As used herein, the terms "amplification primer" and "oligonucleotide primer" are used interchangeably and refer to an oligonucleotide, capable of annealing to an RNA or DNA 50 region adjacent a target sequence, and serving as an initiation primer for DNA synthesis under suitable conditions well known in the art. Typically, a PCR reaction employs an "amplification primer pair" also referred to as an "oligonucleotide primer pair" including an "upstream" or "forward" primer and a "downstream" or "reverse" primer, which delimit a region of the RNA or DNA to be amplified. A first primer and a second primer may be either a forward or reverse primer and are used interchangeably herein and are not to be limiting.

STR Marker/STR Locus: As used herein the terms "STR marker" and "STR locus", and their plural forms, are used to describe one of a set of marker loci suitable for use in genotyping using the method of the present invention. In particular:

"18-3" refers to the STR marker on mouse chromosome 18, corresponding to base pairs 60271556-60271705 (NCBI

6

38.1 mouse build, corresponding to GenBank Accession # NT_039674.8) (SEQ ID NO: 1) (REPEAT MOTIF: [ATCT] n);

"4-2" refers to the STR marker on mouse chromosome 4, corresponding to base pairs 82068280-82068580 (NCBI 38.1 mouse build, corresponding to GenBank Accession # NT_187032.1) (SEQ ID NO: 2) (REPEAT MOTIF: [GATA] n[GATG]n[ATAG]n;

"6-7" refers to the STR marker on mouse chromosome 6, corresponding to base pairs 51601265-51601685 (NCBI 38.1 mouse build, corresponding to GenBank Accession # NT_039353.8) (SEQ ID NO: 3) (REPEAT MOTIF: [CTAT] n);

"9-2" refers to the STR marker on mouse chromosome 9, corresponding to base pairs 74395400-74395000 (NCBI 38.1 mouse build, GenBank Accession # NT039474.8) (SEQ ID NO: 4) (REPEAT MOTIF: [TAGA]n[AGAT]n);

"15-3" refers to the STR marker on mouse chromosome 15, corresponding to base pairs 4930200-4930500 (NCBI 38.1 mouse build, GenBank Accession # NT_039617.8) (SEQ ID NO: 5) (REPEAT MOTIF: [TAGA]n);

"6-4" refers to the STR marker on mouse chromosome 6, corresponding to base pairs 142021975-142022270 (NCBI 38.1 mouse build, GenBank Accession # NT_039360.8) (SEQ ID NO: 6) (REPEAT MOTIF: [ATAG]n[ATGA]n [TAGA]n);

"12-1" refers to the STR marker on mouse chromosome 12, corresponding to base pairs 38480950-38481170 (NCBI 38.1 mouse build, GenBank Accession # NT_039548.8) (SEQ ID NO: 7) (REPEAT MOTIF: [AGAT]n[GATA]n);

"5-5" refers to the STR marker on mouse chromosome 5, corresponding to base pairs 112641540-112641820 (NCBI 38.1 mouse build, GenBank Accession # NT_109320.5) (SEQ ID NO: 8) (REPEAT MOTIF: [TATC]n); and

"X-1" refers to the STR marker on mouse chromosome X, corresponding to base pairs 110959842-110960080 (NCBI 38.1 mouse build, GenBank Accession # NT_039706.8) (SEQ ID NO: 9) (REPEAT MOTIF: [ATAG]n[ATGA]n [TAGA]n).

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which these teachings belong. All patents, patent applications, published applications, treatises and other publications referred to herein, both supra and infra, are incorporated by reference in their entirety. If a definition and/or description is set forth herein that is contrary to or otherwise inconsistent with any definition set forth in the patents, patent applications, published applications, and other publications that are herein incorporated by reference, the definition and/or description set forth herein prevails over the definition that is incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present teachings are not entitled to antedate such publication by virtue of prior disclosure.

# DETAILED DESCRIPTION OF THE DISCLOSURE

The present disclosure relates to a method and kit for mouse cell line authentication. The method and kit disclosed herein target tetranucleotide repeats in the mouse genome including primers that amplify nine mouse short tandem repeat (STR) markers. Based on unique profiles obtained from seventy-two (72) mouse samples, the allele distribution for each short tandem repeat (STR) marker was determined. Correlations between allele fragment length and repeat

number were confirmed with sequencing. The STR markers may be stable up to passage forty-five in L929 and NIH3T3 cell lines as there were no significant differences in fragment length in samples of low passage when compared to high passage samples. Primer sets for two human STR markers were incorporated into the multiplex method and kit to facilitate detection of human cell line contaminants. Adoption of this simple method and kit would provide assurance in cell line identity for researchers and cell repositories. The method and kit provide a unique STR profile for each individual mouse sample and can be used to authenticate mouse cell lines.

Target STR markers were chosen for each chromosome, including the X and Y chromosomes, by searching for tetranucleotide repeat sequences (AGAT and TCTA) within the mouse genome using the National Center for Biotechnology Information (NCBI) BLAST program Primers were tested to meet three requirements. First, the locus must be present in every sample tested. Second, the locus must 20 contain a tetranucleotide repeat. Third, primers for each marker must amplify products in a functional multiplex.

Two markers were located on mouse chromosome six; however, they were 90 megabases (Mb) apart and on opposite arms of the chromosome and were considered unlinked. 25 In humans, markers that are over 50 Mb apart have been considered unlinked.

Two well-characterized human STR markers, D8S1106 and D4S2408, may be included in the multiplex kit (sometimes referred to hereinafter as an "assay"). These markers 30 may be used to screen for contamination of mouse cell lines with human or African green monkey cell lines. Both human STR markers can be used to identify human and African green monkey cell lines (e.g., Vero cells).

Primer3 software, available online from the Massachusetts Institute of Technology, may be used to design PCR primers to flank the STR regions by inputting the downloaded mouse sequences from the NCBI BLAST program. The parameters for Primer3 were set to target primers with annealing temperatures of 60° C. AUTODIMERTM software 40 was used to assess primer-dimer interactions and hairpin structures of possible primer combinations to be used in the multiplex. Forward primers were labeled with one of the following fluorescent dyes at the 5' end: 6FAMTM (blue), VICTM (green), NEDTM (yellow), or PETTM (red) (Applied 45 Biosystems, Foster, Calif.). In some cases, an additional guanine base (G) or a "PIGtail" sequence (GTTTCTT) was added to the 5' end of the unlabeled reverse primers to promote complete adenylation.

Referring now to FIG. 1, illustrated is a table showing the primers used for STR amplification and their corresponding chromosomal locations. In FIG. 1, mouse chromosomal locations, or base pairs (bp), are based on NCBI BLAST 38.1 mouse build. Chromosomal locations for human STR markers D8S1106 and D4S2408 are based on the NCBI 37.3 55 human build. Primer concentrations in the rightmost column are final concentrations of forward and reverse primers in a 20 µL reaction volume. Primer concentrations were determined empirically based on peak height, DNA concentration and the number of cycles in the PCR program.

Based on FIG. 1, the exemplary amplification primers are set forth below. In order to specifically amplify the selected STR markers, the following oligonucleotide primer pairs were used, where "F" and "R" correspond to the forward and reverse primers respectively. The PCR is the product 65 expected from amplification of the particular STR locus to which the oligonucleotide pair was directed.

8

18-3: F-TCTTCTCCTTTTGTGTCATGC	(SEQ ID NO: 10)
R-GTTTCTTGCTAAATAACTAAGCAAGTGAAC	(SEQ ID NO: 11) AGA
Primer	(SEQ ID NO: 1)
4-2:	
F-AAGCTTCTCTGGCCATTTGA	(SEQ ID NO: 12)
R-GTTCATAAACTTCAAGCAATGACA	(SEQ ID NO: 13)
Primer	(SEQ ID NO: 2)
6-7:	
F-AGTCCACCCAGTGCATTCTC	(SEQ ID NO: 14)
R-GTTTCTTCATGTGGCTGGTATGCTGTT	(SEQ ID NO: 15)
Primer	(SEQ ID NO: 3)
9-2:	
F-GGATTGCCAAGAATTTGAGG	(SEQ ID NO: 16)
R-GTTTCTTTCCTGAGTTGTGGACAGGGTTA	(SEQ ID NO: 17)
Primer	(SEQ ID NO: 4)
15-3 :	
F-TCTGGGCGTGTCTGTCATAA	(SEQ ID NO: 18)
R-GTTTCTTTCTCAGGGAGGAGTGTGCT	(SEQ ID NO: 19)
Primer	(SEQ ID NO: 5)
6-4:	
F-TTTGCAACAGCTCAGTTTCC	(SEQ ID NO: 20)
R-GTTTCTTAATCGCTGGCAGATCTTAGG	(SEQ ID NO: 21)
Primer	(SEQ ID NO: 6)
12-1:	(SEQ ID NO: 22)
F-CAAAATTGTCATTGAACACATGTAA	
R-GTTTCTTTCAATGGTCAAGAAATACTGAAG	(SEQ ID NO: 23) TACAA
Primer	(SEQ ID NO: 7)
5-5:	
F-CGTTTTACCTGGCTGACACA	(SEQ ID NO: 24)
R-GTTTCTT <i>T</i> GGTTTAAAACTCAATACCAAAC	(SEQ ID NO: 25) AA
	(SEQ ID NO: 8)
Primer	2

### -continued

X-1:	(SEQ ID NO: 26)
F-GGATGGATGGATGAAA	(BEQ ID NO. 20)
R-GTTTCTTAAGGTATATCAAGATGGCATTA	(SEQ ID NO: 27)
Primer	(SEQ ID NO: 9)
D8S1106:	(CEO ID NO. 20)
F-GTTTACCCCTGCATCATGG	(SEQ ID NO: 30)
R-GTTTCTTTCAGAATTGCTCATAGTGCAAGA	(SEQ ID NO: 31)
Primer	(SEQ ID NO: 28)
D4S2408:	(CEO ID NO 20)
F-TCATTTCCATAGGGTAAGTGAAAA	(SEQ ID NO: 32)
R-GTTTCTTGCCATGGGGATAAAATCAGA	(SEQ ID NO: 33)
Primer	(SEQ ID NO: 29)

Genomic mouse DNA samples were obtained from Jackson Laboratories (Bar Harbor, Me., USA). These samples represent 48 common inbred strains used in the scientific community. The DNA included thirty-seven inbred mice 30 DNA samples, one recombinant inbred mouse sample, and ten wild-derived mice DNA samples. DNA from 15 wild-caught mice (courtesy of Dr. Michael Nachman from the University of Arizona, USA) collected in Tucson, Ariz. was used for heterozygosity studies.

Genomic DNA from mouse (male and female CD1/ICR), hamster (Syrian golden hamster, Chinese hamster), rat (Fischer, Wistar, Sprague Dawley), gerbil, pig, baboon, rhesus, and cynomolgus monkey were obtained from Zyagen (San Diego, Calif.). TN1 cells (stably transfected green fluoresent protein (GFP) expressing cell line derived from the parent NIH3T3 line) were originally obtained from the American Type Culture Collection, Manassas, Va., in 2003. The following cell lines were obtained from The American Type Culture Collection (ATCC, Manassas, Va.): NIH3T3 45 (CRL-1658), L-929 (CCL-1), MC3T3-E1 subclone 4 (CRL-2593), RAW 264.7 (TIB-71), M. dunni (CRL-2017), P3X63Ag8.653 (CRL-1580), HK-PEG-1 (CCL-189), Vero (CCL-81), HeLa (CCL-2), and CHO-K1 (CCL-61).

DNA was quantified using the SYNERGYTM Mx plate 50 reader and TAKE3TM plate (BioTek, Winooski, Vt., USA) at an absorbance of 260 nm. To study STR marker stability as passage number increased, duplicate 25 cm² tissue culture flasks of L929 cells were carried independently, and one million cells were harvested at passage numbers 2, 4, 9, 14, 55 19, 22, 26, 29, 31, 37, 41, and 44. Duplicate 25 cm² flasks were also carried for NIH3T3 cells which were carried independently, and one million cells were harvested from passage numbers 5, 7, 10, 15, 20, 23, 26, 32, 35, 40, 43, and 45.

PCR amplification was performed on a VERITITM thermal cycler (Applied Biosystems). The reaction mixture of 20  $\mu$ L final volume contained 1 ng of mouse DNA (or 5 ng to 10 ng of non-mouse DNA for specificity studies), 1× GENEAMP® PCR Gold buffer (Applied Biosystems), 2 65 mM MgCl₂ (Applied Biosystems), 250  $\mu$ M dNTPs (USB Corporation, Cleveland, Ohio, USA), forward labeled and

**10** 

reverse primers (as shown in FIG. 1 hereinabove), 1U AMPLITAQ GOLDTM DNA Polymerase (Applied Biosystems), and 0.16 mg/mL non-acetylated BSA (Invitrogen). PCR conditions for the multiplex assay are as follows: denaturation for 11 min at 95° C., amplification for 30 cycles of 45 s at 94° C., 2 min at 59° C., and 1 min at 72° C., followed by an extension for 60 min at 60° C., and a final soak at 25° C.

Initial unlabeled primers and their respective PCR prod-10 ucts were screened by using gel electrophoresis. PCR products (4  $\mu$ L) were added to the Lonza 5× loading dye (1  $\mu$ L), loaded onto a 2.2% agarose Flash Gel (Lonza) and run at 275 V for 5 min. Forward primers generating clean PCR products were ordered with a fluorescent dye at the 5' end and 15 were tested in monoplex reactions with mouse DNA from Jackson Laboratories, Zyagen, and mouse cell lines. Multiplex reactions were then optimized by varying primer combinations, primer concentrations, DNA concentration, and PCR cycle number. To analyze monoplex and multiplex 20 PCR products, samples were prepared by adding 1 μL of amplified product and 0.3  $\mu L$  of GENESCANTM 500 LIZ internal size standard (Applied Biosystems) to 8.7 µL of HI-DITM formamide (Applied Biosystems) for separation on the 16-capillary ABI 3130×1 Genetic Analyzer (Applied 25 Biosystems). A five dye matrix was established under the G5 filter with dyes 6FAM, VIC, NED, PET, and LIZ. POP-4TM (Applied Biosystems) was used on a 36 cm capillary array (Applied Biosystems) with  $1 \times ACE^{TM}$  buffer (Amresco, Solon, Ohio, USA). Samples were injected electrokinetically for 10 s at 3 kV. The STR alleles were separated at 15 kV at a run temperature of 60° C. Data from the 3130×1 genetic analyzer was analyzed using the GENEMAPPERTM ID-X v1.1 Software (Applied Biosystems). Bins and panels were created in GENEMAPPERTM ID-X based on fragment 35 length data generated from the fifty-seven mouse profiles using fixed bin allele sizes to determine allele calls. The allele distribution range for the human STR markers (D8S1106 and D4S2408) was previously described and adjustments were made to the size range to take into account the "PIGtail" sequence that was added to the reverse primers. Calibration of repeat number to allele fragment length was determined by DNA sequencing.

Multiplex primers were used for sequencing STR markers, except for three loci (18-3, 9-2, and 12-1) where sequencing primers were used. Referring now to FIG. 2, illustrated are the forward and reverse primers used to sequence each of the nine STR markers. Also shown in FIG. 2 are the corresponding annealing temperatures and amplicon sizes for these markers.

At least four homozygous samples were sequenced for each STR locus to determine the corresponding number of repeats for each allele. The targeted repeat regions were amplified using 0.15 µM unlabeled forward and reverse primers using the PCR reaction specified herein in connection with PCR amplification with the following thermal cycling program: denaturation for 10 min at 95° C., amplification for 35 cycles of 1 min at 94° C., 1 min at 52-60° C. (annealing temperature specific to individual primers), and 1 min at 72° C., followed by an extension for 45 min at 60° 60 C., and a final soak at 25° C. Samples were treated with 2 μL of EXOSAP-IT® PCR product cleanup (USB Corporation) per 5 µL of PCR product. This product cleanup was used to remove unincorporated primers and deoxyribonucleotide triphosphates (dNTPs) by incubating samples for 90 min at 37° C. followed by 20 min at 80° C. to inactivate the enzymes. Samples were then sent to Eurofins MWG Operon for sequencing using BIGDYE® Terminator v3.1 (Applied

Biosystems). Resulting profiles were received after data analysis was performed by Eurofins MWG Operon.

Mixture samples containing genomic DNA extracted from NIH3T3, RAW264.7, and HeLa cells were analyzed to assess the capability of the multiplex assay to detect low 5 levels of contamination in NIH3T3 cells. DNA from NIH3T3 and RAW264.7 cells were added to individual reactions with a final concentration of 1 nanogram (ng) of total DNA in the following ratios 1:1, 2:1, 3:1, 5:1, 7:1, 9:1, and 10:1. Reciprocal reactions were also prepared using DNA from RAW264.7 and NIH3T3 cells. The same procedure was repeated using DNA from NIH3T3 and HeLa cells, followed by reciprocal reactions with DNA from HeLa and NIH3T3 cells. PCR amplification and PCR product analysis are described above.

The heterozygosity (H) values were calculated by dividing the number of heterozygotes at a locus into the total number of individuals. The probability of identity (PI) was calculated by the summation of the square of the genotype frequencies. The probability of a random match (PM) for a 20 full profile was calculated by multiplying the inverse of each genotype frequency for each marker. The coefficient of inbreeding (F), specifically the fixation in a subpopulation compared to the total population (FST) was determined by subtracting the average heterozygosity of the two subpopulations (wild-caught mice and inbred mice samples) from the total heterozygosity, divided by the total heterozygosity.

The mouse primers targeting tetranucleotide repeat markers in the multiplex PCR assay were designed based on the annotated mouse genome from NCBI build 38.1 of Mus 30 musculus origin. Fifty-seven genomic mouse DNA samples were tested using the multiplex assay and the designated allele range was determined for each marker, and fragment lengths were correlated to actual number of repeats using sequence analysis.

Referring now to FIG. 3, illustrated is a table defining STR fragment length and corresponding repeat number in accordance with the present disclosure. In FIG. 4, fragment length in base pairs corresponds to apparent size based on LIZ GENESCAN® 500 size standard. The corresponding 40 number of repeats are each shown just below the fragment length. The corresponding number of repeats was determined by the analysis of 57 mouse DNA samples. The correlation of the allele size and number of repeats was determined based on sequencing data.

The mouse samples were selected to represent the genetic diversity of the mouse family tree. To determine the specificity of the multiplex assay, DNA was tested from several different species and subspecies of mice, near neighbors, and non-mouse samples. A panel of 57 mouse genomic DNA 50 samples representing species from M. musculus musculus, M. musculus domesticus, M. musculus molossinus, M. musculus castaneus, M. spretus (Spain), and M. dunni were tested with the multiplex PCR primers to determine assay robustness. Full unique profiles amplified in the designated 55 allele range were obtained from the panel for all but the following samples: CAST/EiJ (M. musculus castaneus), JF1/Ms (M. musculus molossinus), SPRET (M. spretus), and M. dunni cell line. DNA from CAST and JF1 mice resulted in amplicons for each marker. However, the PCR 60 product was outside of the designated allele range for the 18-3 and 6-7 loci, respectively. Sequencing the CAST mouse DNA revealed that this sample has conserved sequence flanking the repeat region. However, fifty-two ATCT repeats were observed at this locus. Thus, twenty-nine 65 more repeats were observed at this locus than in the designated allele range.

12

Because of additional repeats present in the CAST mouse sample, the amplified product appears between STR markers 4-2 and 6-7. All M. musculus molossinus samples resulted in full profiles except for DNA from the JF1 mouse which amplified outside the designated allele range for marker 6-7. The additional thirty-two repeats that JF1 contains at the 6-7 locus may be explained in the origin of Mus musculus molossinus, a natural hybrid of M. m. musculus and M. m. castaneus, the latter shown to deviate from the designated allele range at marker 18-3.

DNA from the SPRET mouse (M. spretus) results in amplicons that fall outside the designated allele range for the following loci: 18-3, 4-2, 15-3, and X-1. The SPRET sample was sequenced at the 18-3 locus resulting in sixty-six 15 repeats, eleven of which were GTCT repeats embedded within the defined ATCT repeat for this marker. DNA extracted from the M. dunni cell line does not amplify at the 6-4 STR marker and falls outside the designated allele range for X-1. Further analysis of DNA from M. dunni and SPRET was not continued as their profiles were incomplete using the multiplex assay. Interestingly, CAST and SPRET are mapped together in group 2 in a published mouse family tree. However, full profiles within the allele range are observed for the other members in that group including PERC (M. m. domesticus), MOLG (M. m. molossinus), and MOLF (M. m. molossinus).

A panel of rodent and porcine DNA (rat, hamster, gerbil, pig), human cell lines (HeLa, HEPM, SK-BR-3, MCF10A) and nonhuman primate DNA samples (Vero, COS-7, rhesus, baboon, cynomolgus monkey) were tested with the multiplex assay to determine assay specificity. None of these samples resulted in a complete profile using the primers targeting mouse STR markers. DNA from Wistar, Fischer, and Sprague-Dawley rats resulted in a single amplified 35 product in the red dye channel; however, each sample resulted in an amplicon with a fragment length of 219 base pairs. Characteristic stutter peaks associated with polymerase slippage of repeat regions were absent in the rat samples. Lack of stutter peaks and identical amplicon sizes for each rat strain suggests the peak present is most likely a PCR artifact rather than amplification of a repeat region. Amplification products were absent for each mouse STR marker when DNA from human and African green monkey cell lines were tested. However, both cell lines amplified at 45 the human STR markers (D8S1106 and D4S2408) present in the multiplex as expected. No significant amplicons were visible for pig, hamster, or gerbil DNA.

SNP assays, commonly used to type mouse strains, are efficient in discriminating between different strains of mice, but may not be ideal in differentiating between cell lines derived from the same substrain. SNPs are mostly bi-allelic markers whereas STR markers typically have greater than five alleles. Using the mouse multiplex assay, unique profiles were obtained for the mouse cell lines listed in FIG. 5 with the capability of distinguishing between three Balb/c-derived cell lines. FIG. 5 is a table illustrating the complete genetic profiles of six mouse cell lines in accordance with the present disclosure.

In FIG. 4, the repeat numbers are listed for each locus. Microvariants are indicated by a decimal point. As shown in FIG. 4, there are many conserved alleles between the three Balb/c-derived samples; however, there are sufficient differences resulting in unique profiles for each individual cell line. Two of the Balb/c-derived cell lines, mouse myeloma cells (P3X63Ag8.653) and hybridoma cells (HK-PEG-1), are very similar in their genotype, only varying by one allele at the 9-2 locus. The HK-PEG-f cell line was produced by

fusing P3X63Ag8.653 (myeloma cells originating from a BALB/c mouse) with spleen cells from a BALB/c mouse, explaining why they share so many alleles. The myeloma cell line is heterozygous at the 9-2 locus whereas the hybridoma cell line is homozygous. To verify the presence 5 of a null allele at the 9-2 marker, a panel of primers was tested with DNA from the hybridoma cells resulting in amplicons ranging from 132 to 244 base pairs (bp). Homozygote peaks were present in each sample, supporting the findings that these two cell lines differ by one allele at 10 this marker.

To test assay sensitivity and determine the lower limits of detection, DNA from NIH3T3, HeLa, and Vero cell lines was diluted from 6 nanograms (ng) to 7.8 picograms (pg). A full profile for NIH3T3 cells was obtained using 62 pg of 15 DNA but resulted in a loss of an allele at one mouse STR markers at 31 pg of DNA. The two human STR markers were also tested and resulted in peaks above the analytical threshold (50 relative fluorescent units) for HeLa and Vero cell lines using 62 and 187 pg of DNA, but resulted in allelic 20 drop-out at 31 and 93 pg of DNA, respectively. In previous studies, higher concentrations of Vero cell DNA (6 ng) were needed to obtain an STR profile using human STR markers when compared to human DNA (0.5-1 ng). This is consistent with the higher concentrations of Vero DNA needed in this 25 study to amplify efficiently using the human STR markers in the multiplex assay.

The multiplex assay described herein was designed to detect human or African green monkey cell line contamination of mouse cells by incorporating two human STR 30 markers that amplify outside the designated allele ranges for the nine mouse STR markers. Mixture ratios ranging from 1:1 to 10:1 of NIH3T3 and HeLa DNA were tested to model contamination scenarios.

the NIH3T3 cell line using the multiplex assay of the present disclosure. An electropherogram depicting a pure NIH3T3 STR profile is shown in this FIG. 7.

Referring now to FIG. 6, illustrated is a human contaminant detected in the NIH3T3 STR profile. A 1:1 ratio of 40 NIH3T3 and HeLa DNA is shown in this FIG. 8. Even at the lowest dilution of HeLa DNA (90 pg), human STR markers were detected above the analytical threshold. The assay can also be used to detect a mixture of multiple mouse cell lines.

Referring now to FIG. 7, illustrated is a genetic profile of 45 the RAW 264.7 cell line using the mouse multiplex assay (1) ng DNA). This electropherogram depicts a pure RAW264.7 STR profile. Mixture ratios ranging from 1:1 to 10:1 of NIH3T3 and RAW264.7 DNA were tested and full profiles of both cell lines were present even at the lowest DNA 50 dilution (90 pg).

Referring now to FIG. 8, illustrated is a mixture of NIH3T3 and RAW 264.7 mouse cell lines detected using the assay described herein. FIG. 10 shows a 1:1 mixture of the two mouse cell lines.

The majority of mouse cell lines are derived from inbred mice resulting in alleles that are mostly homozygous in nature. For example, as shown earlier in connection with FIG. 4, the RAW 264.7 mouse cell line is homozygous at each STR marker. Multiple alleles present at each locus 60 could indicate a mixed population of cells. Triallelic patterns have been observed in some human cell lines at a particular locus, which may or may not be equal in intensity. The L929 cell line appears to have three alleles with similar peak height intensities at the 15-3 marker and each allele is four 65 base pairs or one repeat apart. Since most of the mouse samples tested were homozygous for the majority of the

14

markers, a panel of primers targeting the 15-3 locus were tested in monoplex with DNA from L929 cells. The amplicons ranged from 210 to 435 base pairs in length and each resulted in three alleles that were four bases apart with very little peak height imbalance. The evidence supports a true triallelic pattern at the 15-3 marker.

Alteration of genetic profiles of some cancer cell lines has been observed previously at high passage numbers. However, other studies show STR stability over high passage numbers in some human cancer cell lines and in African green monkey cell lines. Accordingly, stability may be cell line dependent. To test the stability of the mouse STR markers in this assay, L929 and NIH3T3 cell lines were carried independently and in duplicate flasks up to passage 44 and 45, respectively.

Genotypes were determined and standard deviations were calculated for each locus representing the variations in fragment lengths over all passage numbers. The NIH3T3 cell line resulted in the lowest standard deviation values (0.02-0.05) for each locus. The L929 cell line resulted in standard deviations ranging from 0.05 to 0.14. The STR markers with the highest standard deviations in L929 cells are 6-7 (0.14) and 5-5 (0.13). In both the NIH3T3 and L929 cell lines, even the highest standard deviation values did not result in an allele repeat number change indicating stable STR profiles at high passage numbers. The changes in fragment lengths for each marker over the passage period were not significant enough to change the allele calls and the variability in the amplicon sizes fell within the range of the instrument fluctuation. Identical DNA samples were tested on three different days using the same instrument and the variation in fragment length was ±0.3 base pairs.

In addition to stability of the STR profile for NIH3T3 cells Referring now to FIG. 5, illustrated is a genetic profile of 35 over time, profile stability was evaluated after transfection procedures. The TN1 cell line, derived from NIH3T3 cells obtained from ATCC in 2003 and engineered to express the gene for green fluorescent protein, was analyzed using the multiplex assay and resulted in identical STR profiles for both TN1 and recently obtained NIH3T3 cells. These data support the findings that the STR markers are stable over time in transfected NIH3T3 cell lines.

> The mouse multiplex assay described herein can be used to identify cell lines derived from M. musculus musculus and M. musculus domesticus species. The assay is also useful in identifying M. musculus molossinus and M. musculus castaneus species which amplify at each locus, but in some instances failed to fall within the designated allele range for one of the STR markers. This assay may not be suitable for genotyping mouse cell lines derived from M. spretus (amplicons may fall outside the designated allele range for four STR markers) or M. dunni which may fail to amplify at the 6-4 locus.

Stability studies show the mouse STR markers are stable 55 with high passage numbers and the STR profiles remain unchanged after transfection procedures in the TN1 cell line. Although the STR markers are stable up through passages 44-45, it may be desirable to genotype samples at low passage numbers. The power of discrimination based on the probability of a random match is 1 in 5.7 million using the nine STR markers in the multiplex assay. The assay described in the present disclosure can be used to identify both human and African green monkey cell line contaminants using the two human STR markers incorporated in the multiplex assay in addition to detecting mixtures of mouse cell lines. The targeted tetranucleotide repeat regions in the mouse genome result in unique individual profiles making

this assay more sensitive and specific than those that are currently available. The requirement of cell line authentication is becoming more routine, and this assay provides a reliable method to genotype mouse cell lines.

The STR profiles shown in the Table in FIG. 9 display the allele range for the 9 markers. This data could be used to

**16** 

develop a size reference standard that is a locus-specific allelic ladder.

While the specification describes particular embodiments of the present invention, those of ordinary skill can devise variations of the present invention without departing from the inventive concept.

120

180

228

## SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 50 <210> SEQ ID NO 1 <211> LENGTH: 150 <212> TYPE: DNA <213> ORGANISM: Mouse <400> SEQUENCE: 1 tctttctcct tttgtgtcat gctaactcac aggtattttc tagatggttc catctatcta 120 150 tatatctgtt cacttgctta gttatttagc <210> SEQ ID NO 2 <211> LENGTH: 237 <212> TYPE: DNA <213> ORGANISM: Mouse <400> SEQUENCE: 2 aagcttctct ggccatttga agcatttctg tttgctatat tggttttact atatccaact 60 120 180 237 tgcttataaa atgtgggtta caagaaaaat taaatgtcat tgcttgaagt ttatgaa <210> SEQ ID NO 3 <211> LENGTH: 327 <212> TYPE: DNA <213> ORGANISM: Mouse <400> SEQUENCE: 3 agtccaccca gtgcattctc cagccagtgg agaagaggga gcgcaatggg gacaagtgcc ttttaatttc tatttctttt gttgatgcct gcctgaatgt attctttcta tctatctatc 120 180 tatctatcta tctatctatc tatctatcta tctatcgtat gtgcatgtgt acgacacagc 240 tcatgtgtga aggtcagaag gcaactcccc gggagttggt tctttttcc accatacaga 300 ttctggggaa ttaaagccat cttactggcc ccttagtttg tgtcttagca gcaagtttgg 327 atgacgtaac agcataccag ccacatg <210> SEQ ID NO 4 <211> LENGTH: 228 <212> TYPE: DNA <213> ORGANISM: Mouse <400> SEQUENCE: 4 ggattgccaa gaatttgagg acagtctgtt tcaaatagtg agttttaggc cagcctgaaa

tattgatata ttgggatact gatacacatc tctagataga tagatagata gatagataga

cactgcctaa gagataaatg aaatgttaac cctgtccaca actcagga

-continued

```
<210> SEQ ID NO 5
<211> LENGTH: 196
<212> TYPE: DNA
<213 > ORGANISM: Mouse
<400> SEQUENCE: 5
                                                      60
120
180
atagatgata gacagatata gatgagaaag aaagaaagaa atctatgcat gcattgagca
                                                     196
cactcctccc tgagaa
<210> SEQ ID NO 6
<211> LENGTH: 294
<212> TYPE: DNA
<213> ORGANISM: Mouse
<400> SEQUENCE: 6
tttgcaacag ctcagtttcc ttgagaaaat tgctttaata caaatcccta ggaatctaca
                                                      60
                                                     120
180
ggatagaaag atatcatgta ggctgagata ctacctactt atagtgaagt agtgaaggaa
                                                     240
                                                     294
attcataagc ggtaaataaa aagtattgga actacctaag atctgccagc gatt
<210> SEQ ID NO 7
<211> LENGTH: 224
<212> TYPE: DNA
<213> ORGANISM: Mouse
<400> SEQUENCE: 7
                                                      60
caaaattgtc attgaacaca tgtaaaaaag cagaagatag atagatagat agatagatag
                                                     120
180
gatgtaataa ctaaattgta taatgtgaca ttaaataagt ccatcactat aaaataatct
                                                     224
ttaataatta caaaaagttg tacttcagta tttcttgacc attg
<210> SEQ ID NO 8
<211> LENGTH: 342
<212> TYPE: DNA
<213> ORGANISM: Mouse
<400> SEQUENCE: 8
                                                      60
cgttttacct ggctgacaca cttcctgggc cggtggctcc tggctttgaa agaaatcctt
                                                     120
gatggatgtc ataataaaga ggcttggtgg tgcggagcgc gaggatccgg gttccggttt
                                                     180
atctatctat ctatctatta tttatttatt caggaaatgc ttacttaggg agctgggtag
                                                     240
                                                     300
caaacaaggg ttttctgtac ctgctaggaa caggcaagca tccctaagtc agtttgtagt
                                                     342
ctttattaag caataaattg tttggtattg agttttaaac ca
<210> SEQ ID NO 9
<211> LENGTH: 402
<212> TYPE: DNA
<213> ORGANISM: Mouse
<400> SEQUENCE: 9
                                                      60
```

## -continued

tagatagata gataga	tgatagatag	atagatagat	agatagatag	atagatagat	120	
agatagatag aaagaatgta	atacatatga	gcatactact	cagttttaaa	aattaatttc	180	
tgccatttga tattattgac	ctagaggaaa	atatgttaca	ttaaataacc	tgtggaaatg	240	
agtaggatac cacacaatcc	catttaaatg	ttttatatac	atcttcactg	ctcccgctgt	300	
gacaaatagt gtccttattt	ttgaatgttc	taaaatattt	tgttggttaa	tattcattgt	360	
acatagtcat gaatatgata	atgccatctt	gatatatacc	tt		402	
<210> SEQ ID NO 10 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Mouse						
<400> SEQUENCE: 10						
tctttctcct tttgtgtcat	gc				22	
<210> SEQ ID NO 11 <211> LENGTH: 33 <212> TYPE: DNA <213> ORGANISM: Mouse						
<400> SEQUENCE: 11						
gtttcttgct aaataactaa	gcaagtgaac	aga			33	
<210> SEQ ID NO 12 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Mouse						
<400> SEQUENCE: 12						
aagcttctct ggccatttga					20	
<pre>&lt;210&gt; SEQ ID NO 13 &lt;211&gt; LENGTH: 24 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Mouse &lt;400&gt; SEQUENCE: 13</pre>						
gttcataaac ttcaagcaat	gaca				24	
<210> SEQ ID NO 14 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Mouse						
<400> SEQUENCE: 14						
agtccaccca gtgcattctc					20	
<210> SEQ ID NO 15 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Mouse						
<400> SEQUENCE: 15						
gtttcttcat gtggctggta	tgctgtt				27	
<210> SEQ ID NO 16						

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Mouse

### -continued

<400> SEQUENCE: 16		
ggattgccaa gaatttgagg		20
<210> SEQ ID NO 17 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: Mouse		
<400> SEQUENCE: 17		
gtttctttcc tgagttgtgg	acagggtta	29
<210> SEQ ID NO 18 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Mouse		
<400> SEQUENCE: 18		
tctgggcgtg tctgtcataa		20
<210> SEQ ID NO 19 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Mouse <400> SEQUENCE: 19		
gtttctttc tcagggagga	gtgtgct	27
<210> SEQ ID NO 20 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Mouse		
<400> SEQUENCE: 20		
tttgcaacag ctcagtttcc		20
<210> SEQ ID NO 21 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Mouse		
<400> SEQUENCE: 21		
gtttcttaat cgctggcaga	tcttagg	27
<210> SEQ ID NO 22 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Mouse		
<400> SEQUENCE: 22		
caaaattgtc attgaacaca	tgtaa	25
<210> SEQ ID NO 23 <211> LENGTH: 35 <212> TYPE: DNA <213> ORGANISM: Mouse		
<400> SEQUENCE: 23		
gtttctttca atggtcaaga	aatactgaag tacaa	35
<210> SEQ ID NO 24 <211> LENGTH: 20		

<212> TYPE: DNA

<213> ORGANISM: Mouse

### -continued

<400> SEQUENCE: 24	
cgttttacct ggctgacaca	20
<210> SEQ ID NO 25 <211> LENGTH: 32 <212> TYPE: DNA <213> ORGANISM: Mouse	
<400> SEQUENCE: 25	
gtttctttgg tttaaaactc aataccaaac aa	32
<210> SEQ ID NO 26 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Mouse	
<400> SEQUENCE: 26	
ggatggatgg atggatgaaa	20
<210> SEQ ID NO 27 <211> LENGTH: 34 <212> TYPE: DNA <213> ORGANISM: Mouse	
<400> SEQUENCE: 27	
gtttcttaag gtatatatca agatggcatt atca	34
<210> SEQ ID NO 28 <211> LENGTH: 148 <212> TYPE: DNA <213> ORGANISM: Homo sapiens	
<400> SEQUENCE: 28	
gtttacccct gcatcactgg cccagacagt tgctgctaac ccgcgacaga gagatagaca	60
gatgatagat agatgataga tagatagata gatagata	120
tagattettg caetatgage aattetga	148
<210> SEQ ID NO 29 <211> LENGTH: 324 <212> TYPE: DNA <213> ORGANISM: Homo sapiens	
<400> SEQUENCE: 29	
tcatttccat agggtaagtg aaaaaaattc agcaagttaa gaacttctac atttaaggta	60
cataacagtt caatagaaag ctatgcatct atctatctat ctatctatct atctatctat	120
ctaatggtta ctatttttca gtcatttcag tggatgaatt gaagttgaag tttattgtta	180
atttagttat tctagtatat gtatatcaaa ttccatatgt acaatattca tacaaacaat	240
aataaaaata tttacagtgt cttaatatat gccaagcact cttctaagat tatcatatat	300
ataatctgat tttatcccca tggc	324
<210> SEQ ID NO 30 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens	
<400> SEQUENCE: 30	

gtttacccct gcatcactgg

-continued

gcatgtggct ggtatgctgt t

<210> SEQ ID NO 31	
<211> LENGTH: 30	
<212> TYPE: DNA <213> ORGANISM: Homo sapiens	
<400> SEQUENCE: 31	
gtttctttca gaattgctca tagtgcaaga	3 0
<210> SEQ ID NO 32	
<211> LENGTH: 24	
<212> TYPE: DNA <213> ORGANISM: Homo sapiens	
<400> SEQUENCE: 32	
tcatttccat agggtaagtg aaaa	24
<210> SEQ ID NO 33 <211> LENGTH: 22	
<212> TYPE: DNA	
<213> ORGANISM: Mouse	
<400> SEQUENCE: 33	
tctttctcct tttgtgtcat gc	22
<210> SEQ ID NO 34	
<211> LENGTH: 23	
<212> TYPE: DNA <213> ORGANISM: Mouse	
<400> SEQUENCE: 34	
gtcaaagttg gggttacaga atg	23
geodaageeg gggeedeaga aeg	
<210> SEQ ID NO 35	
<211> LENGTH: 20 <212> TYPE: DNA	
<213> ORGANISM: Mouse	
<400> SEQUENCE: 35	
aagcttctct ggccatttga	20
<210> SEQ ID NO 36 <211> LENGTH: 24	
<212> TYPE: DNA <213> ORGANISM: Mouse	
<400> SEQUENCE: 36	
	O 4
gttcataaac ttcaagcaat gaca	24
<210> SEQ ID NO 37	
<211> LENGTH: 20 <212> TYPE: DNA	
<213> ORGANISM: Mouse	
<400> SEQUENCE: 37	
agtccaccca gtgcattctc	20
<210> SEQ ID NO 38	
<211> LENGTH: 21	
<212> TYPE: DNA <213> ORGANISM: Mouse	
<400> SEQUENCE: 38	
	<b>^1</b>

### -continued

<210> SEQ ID NO 39	
<211> LENGTH: 20	
<212> TYPE: DNA	
<213> ORGANISM: Mouse	
<400> SEQUENCE: 39	
	• •
ggctctctca cacctcatcc	20
<210> SEQ ID NO 40	
<211> LENGTH: 21	
<212> TYPE: DNA	
<213> ORGANISM: Mouse	
<400> SEQUENCE: 40	
	O 4
gtccatgaat ccagacattc c	21
<210> SEQ ID NO 41	
<211> LENGTH: 20	
<212> TYPE: DNA	
<213> ORGANISM: Mouse	
<400> SEQUENCE: 41	
	2.0
tctgggcgtg tctgtcataa	20
<210> SEQ ID NO 42	
<211> LENGTH: 21	
<212> TYPE: DNA	
<213> ORGANISM: Mouse	
<400> SEQUENCE: 42	
attatasaaa saasatataa t	21
gttctcaggg aggagtgtgc t	<b>2</b>
<210> SEQ ID NO 43	
<211> LENGTH: 20	
<212> TYPE: DNA	
<213> ORGANISM: Mouse	
<400> SEQUENCE: 43	
tttgcaacag ctcagtttcc	20
cutguaacag cutagutucu	20
<210> SEQ ID NO 44	
<211> LENGTH: 21	
<212> TYPE: DNA	
<213> ORGANISM: Mouse	
<213> ORGANISM: Mouse	
<213> ORGANISM: Mouse <400> SEQUENCE: 44	21
<213> ORGANISM: Mouse	21
<213> ORGANISM: Mouse <400> SEQUENCE: 44	21
<213> ORGANISM: Mouse <400> SEQUENCE: 44	21
<213> ORGANISM: Mouse  <400> SEQUENCE: 44  gaatcgctgg cagatcttag g	21
<213 > ORGANISM: Mouse  <400 > SEQUENCE: 44  gaatcgctgg cagatcttag g  <210 > SEQ ID NO 45  <211 > LENGTH: 25  <212 > TYPE: DNA	21
<213> ORGANISM: Mouse  <400> SEQUENCE: 44  gaatcgctgg cagatcttag g  <210> SEQ ID NO 45  <211> LENGTH: 25	21
<213 > ORGANISM: Mouse  <400 > SEQUENCE: 44  gaatcgctgg cagatcttag g  <210 > SEQ ID NO 45 <211 > LENGTH: 25 <212 > TYPE: DNA <213 > ORGANISM: Mouse	21
<213 > ORGANISM: Mouse  <400 > SEQUENCE: 44  gaatcgctgg cagatcttag g  <210 > SEQ ID NO 45  <211 > LENGTH: 25  <212 > TYPE: DNA	21
<213 > ORGANISM: Mouse  <400 > SEQUENCE: 44  gaatcgctgg cagatcttag g  <210 > SEQ ID NO 45 <211 > LENGTH: 25 <212 > TYPE: DNA <213 > ORGANISM: Mouse  <400 > SEQUENCE: 45	
<213 > ORGANISM: Mouse  <400 > SEQUENCE: 44  gaatcgctgg cagatcttag g  <210 > SEQ ID NO 45 <211 > LENGTH: 25 <212 > TYPE: DNA <213 > ORGANISM: Mouse	21
<213 > ORGANISM: Mouse  <400 > SEQUENCE: 44  gaatcgctgg cagatcttag g  <210 > SEQ ID NO 45 <211 > LENGTH: 25 <212 > TYPE: DNA <213 > ORGANISM: Mouse  <400 > SEQUENCE: 45	
<213> ORGANISM: Mouse  <400> SEQUENCE: 44  gaatcgctgg cagatcttag g  <210> SEQ ID NO 45 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Mouse  <400> SEQUENCE: 45  caaaattgtc attgaacaca tgtaa	
<213 > ORGANISM: Mouse  <400 > SEQUENCE: 44  gaatcgctgg cagatcttag g  <210 > SEQ ID NO 45 <211 > LENGTH: 25 <212 > TYPE: DNA <213 > ORGANISM: Mouse  <400 > SEQUENCE: 45  caaaattgtc attgaacaca tgtaa  <210 > SEQ ID NO 46	
<213 > ORGANISM: Mouse  <400 > SEQUENCE: 44  gaatcgctgg cagatcttag g  <210 > SEQ ID NO 45 <211 > LENGTH: 25 <212 > TYPE: DNA <213 > ORGANISM: Mouse  <400 > SEQUENCE: 45  caaaattgtc attgaacaca tgtaa  <210 > SEQ ID NO 46 <211 > LENGTH: 28	
<213 > ORGANISM: Mouse  <400 > SEQUENCE: 44  gaatcgctgg cagatcttag g  <210 > SEQ ID NO 45 <211 > LENGTH: 25 <212 > TYPE: DNA <213 > ORGANISM: Mouse  <400 > SEQUENCE: 45  caaaattgtc attgaacaca tgtaa  <210 > SEQ ID NO 46	
<213> ORGANISM: Mouse  <400> SEQUENCE: 44  gaatcgctgg cagatcttag g  <210> SEQ ID NO 45 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Mouse  <400> SEQUENCE: 45  caaaattgtc attgaacaca tgtaa  <210> SEQ ID NO 46 <211> LENGTH: 28 <212> TYPE: DNA	

-continued

gcaatggtca agaaatactg aagtacaa	28	
<210> SEQ ID NO 47		
<211> LENGTH: 20		
<212> TYPE: DNA <213> ORGANISM: Mouse		
(ZIS) ORGANISM. MOUSE		
<400> SEQUENCE: 47		
cgttttacct ggctgacaca	20	
<210> SEQ ID NO 48		
<211> LENGTH: 20		
<212> TYPE: DNA		
<213> ORGANISM: Mouse		
<400> SEQUENCE: 48		
gatgcttgcc tgttcctagc	20	
<210> SEQ ID NO 49		
<211> LENGTH: 20		
<212> TYPE: DNA		
<213> ORGANISM: Mouse		
<400> SEQUENCE: 49		
ggatggatgg atggatgaaa	20	
<210> SEQ ID NO 50		
<211> LENGTH: 28		
<212> TYPE: DNA		
<213> ORGANISM: Mouse		
<400> SEQUENCE: 50		
gaaggtatat atcaagatgg cattatca	28	

We claim:

1. A method of determining the alleles present in a DNA sample, the method comprising:

obtaining a DNA sample to be analyzed;

selecting a set of STR marker loci of the DNA sample to be analyzed that can be amplified together in a multiplex amplification reaction, wherein the set of STR marker loci are selected from the group consisting of: 45 18-3, 4-2, 6-7, 9-2, 15-3, 6-4, 12-1, 5-5 and X-1;

providing a set of oligonucleotide primer pairs, wherein each oligonucleotide primer pair in the set flanks a single locus in the set of STR marker loci, and wherein each oligonucleotide primer pair is capable of amplification of a single locus from the set of STR marker loci in a multiplex amplification reaction;

- co-amplifying the set of STR marker loci in a multiplex amplification reaction, wherein the product of the multiplex amplification reaction comprises a mixture of amplified alleles from each of the co-amplified loci in the set of STR marker loci;
- evaluating the products of the co-amplification reaction to determine the alleles present at each of the loci analyzed in the set of STR marker loci within the DNA sample; and
- wherein the source of the DNA sample to be analyzed is at least one of a mouse and a cell line derived from a mouse.
- 2. The method of claim 1, wherein the mouse is selected from the group consisting of Mus musculus musculus, Mus musculus domesticus, Mus musculus molossinus and Mus musculus castaneus.

3. The method of claim 1, wherein the DNA sample to be analyzed comprises DNA derived from at least two different mouse sources.

**30** 

- 4. The method of claim 1, wherein the DNA sample to be analyzed further comprises DNA derived from at least one other source that is a non-mouse source.
- 5. The method of claim 4, wherein the non-mouse source is at least one of human and African green monkey.
- 6. The method of claim 5, wherein the set of oligonucleotide otide primer pairs further comprises an oligonucleotide primer pair configured to amplify an STR allele from the non-mouse source.
- 7. The method of claim 1, wherein at least one oligonucleotide primer in each oligonucleotide pair comprises a detection label.
- 8. The method of claim 7, wherein the detection label comprises a fluorescent dye.
- 9. The method of claim 8, wherein evaluating the products of the co-amplification reaction comprises measuring fluorescence emission upon excitation of the detection label with light.
  - 10. The method of claim 7, comprising using at least four oligonucleotide primer pairs, wherein at least one primer of each oligonucleotide primer pair is labeled with a detection label, and wherein at least four different detection labels are used.

* * * * *